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The ability to study adipose tissue in vivo has centered around the use of transgenic mice, 
which require significant time, resources, and investment to generate. With nearly 40% 
of adults in the United States considered obese, efficient strategies to improve the way in 
which adipose tissue is investigated are paramount. Recently, viral or nonviral delivery of 
CRISPR/Cas9 for inducible gene knockout in somatic tissues has been used to efficiently 
model disease and study gene function. Its use in adipose tissue, however, has not been 
attempted owing to an inability to target adipocytes in vivo.  
My dissertation work sought to identify novel delivery strategies that would enable 
CRISPR/Cas9 inducible gene knockout in adipose tissue. To accomplish this, I explored 
the use of adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs) for targeting 
adipose tissue in vivo. I demonstrated that vector and route of administration are the two 
key factors that govern adipocyte transduction efficiency. Local delivery of AAV serotype 
8 was shown to maximize adipocyte transduction specifically in brown adipose tissue 
(BAT). I thus applied this delivery strategy to attempt CRISPR/Cas9 inducible gene 
knockout in BAT of adult mice.  
I developed the Brown Adipocyte CRISPR (BAd-CRISPR) method, in which AAV8 
is used to deliver a single guide RNA (sgRNA) to mice expressing Cas9. I generated a 
brown adipocyte Cas9-expressing mouse line and developed a cloning pipeline that 
enabled sgRNAs targeting any gene to be packaged into AAV8 and locally injected to 
BAT. BAd-CRISPR allowed for rapid interrogation of one or multiple genes and was used 
to knockout adiponectin (ADIPOQ), adipose triglyceride lipase (ATGL), fatty acid 
synthase (FASN), perilipin 1 (PLIN1), and stearoyl-CoA desaturase 1 (SCD1) specifically 
in BAT of adult mice. Importantly, BAd-CRISPR did not result in accumulation of 
substantial off-target mutations. These studies demonstrated that the BAd-CRISPR 
 xix 
method can be used to inducibly knockout genes in BAT and that transgenic mice can be 
generated in 1-2 months. 
BAd-CRISPR was then used to generate the first inducible uncoupling protein 1 
(UCP1) knockout mouse and assess the effects of UCP1 loss on adaptive thermogenesis 
in adult mice. Inducible UCP1 knockout mice defend core body temperature at 20-21ºC 
and at 5ºC despite complete loss of UCP1 expression. Interestingly, inducible UCP1 
knockout led to an upregulation of genes involved in peroxisomal lipid oxidation and 
protein synthesis and turnover, and a decrease in genes involved in mitochondrial 
metabolism, suggesting a compensatory mechanism to maintain adaptive 
thermogenesis. 
Ultimately, my doctoral work produced an efficient method to streamline the paths 
to discovery in BAT. This work demonstrated that CRISPR/Cas9 can be harnessed to 
generate BAT specific gene knockout models that require less financial investment and 
substantially reduced time compared to traditional transgenic approaches. Given the 
utility of this method, it is expected that with further optimization, BAd-CRISPR will be 
applicable not only to white and marrow adipose tissues, but also adapted for use in other 
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ABSTRACT 
Gene transfer using viral or nonviral vectors enables the ability to manipulate specific cells 
and tissues for gene silencing, protein overexpression, or genome modification. Despite 
the widespread application of viral and nonviral mediated gene transfer to liver, heart, 
skeletal muscle, and the central nervous system, its use in adipose tissue has been 
limited. This is largely because adipose tissue is distributed throughout the body in distinct 
depots and adipocytes make up a minority of the cells within the tissue, making 
transduction difficult. Currently, there is no consensus methodology for efficient gene 
transfer to adipose tissue and many studies report conflicting information with regard to 
transduction efficiency and vector biodistribution. In this review, we summarize the 
challenges associated with gene transfer to adipose tissue and report on innovations that 
improve efficacy. We describe how both vector and route of administration are the two 
key factors that influence transduction efficiency and outline a “gold standard” approach 
and experimental workflow for validating gene transfer to adipose tissue. Lastly, we 
speculate on how CRISPR/Cas9 can be integrated to improve adipose tissue research. 
 
I. VIRAL AND NONVIRAL GENE TRANSFER TO ADIPOSE TISSUE 
 
Introduction to Gene Transfer 
Our understanding of physiology is heightened by our ability to manipulate cells and 
tissues. Through gene transfer, we can deliver genetic agents for gene silencing, protein 
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overexpression, or genome modification to further our understanding of biological 
phenomena. To accomplish gene transfer in a tissue-specific manner, one must consider 
two critical components: the vector and the route of administration. An ideal vector shields 
its cargo from degradation, targets a specific tissue, facilitates unloading of its cargo into 
cells, and evades the host immune response. Both viral and nonviral vectors meet these 
criteria (1-3). Secondly, to ensure the vector reaches its desired destination, an 
appropriate route of administration must be determined. In general, vectors are 
administered systemically or locally, depending on the tissue of interest. Gene transfer 
has largely been aimed at the liver, heart, skeletal muscles, and the central nervous 
system, however, its application to adipose tissue has been met with limited success. 
Collectively, adipose tissues comprise the largest endocrine organ in the body with 
important regulatory functions for energy balance and metabolism, thus making it an 
attractive focal point for understanding obesity and the metabolic syndrome. In this 
section, we will outline how both vector and route of administration influence transduction 
efficiency. By carefully optimizing these two factors, gene transfer can be accomplished 
in an adipose-specific fashion. 
 
Targeting Adipose Tissue: Challenges and Limitations 
Adipocytes are located throughout the body mainly in subcutaneous, visceral, and 
marrow depots as white (WAT), brown (BAT), or more specialized adipose tissues (4-6). 
At the cellular level, mature adipocytes comprise only 11-40% of the total cell population 
in adipose tissue, which also contains preadipocytes, stem cells, macrophages, 
endothelial cells, and vasculature, collectively referred to as stromal vascular cells (7). 
WAT constitutes the bulk of adipose tissue and is found in subcutaneous and visceral 
depots. In mice, the subcutaneous WAT includes the interscapular, subscapular, axillary, 
and cervical depots in the anterior, and the dorso-lumbar, inguinal, and gluteal depots in 
the posterior. Subcutaneous WATs are also closely associated with lymphatic tissues and 
in females comprise part of the mammary glands. Visceral adipocytes are contained 
within the peritoneal cavity and include the mesenteric, perirenal, retroperitoneal, and 
gonadal (epididymal/ovarian) depots. An inability to expand these depots to store excess 
energy is typically associated with insulin resistance and metabolic dysfunction (5,6). 
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Additionally, there are several smaller depots including the intramuscular, periarticular, 
paracardial, epicardial, retro-orbital, and dermal WAT. By contrast, BAT is predominantly 
found in the interscapular depot, but also in the periaortic, perirenal, and intercostal 
depots (8). Brown adipocytes are characterized by a multilocular lipid droplet morphology 
and are rich in mitochondria (4-6,8). In response to temperatures below thermoneutrality 
(<~30°C in mice), brown adipocytes express uncoupling protein 1 (UCP1), a key 
mechanism for adaptive non-shivering thermogenesis (8). Although much smaller in 
terms of adipose tissue mass, BAT metabolism is the predominant energy consumer in 
mice at cold temperatures, making it an attractive therapeutic target for treating obesity 
(8,9). 
Given the diversity and distribution of adipose tissue, gene transfer has remained 
challenging. In vivo manipulation has been limited to the generation of Cre-Lox and/or 
drug-inducible transgenic models. Cre-Lox systems enable the expression of Cre 
recombinase under the control of adipocyte-specific promoters. Several adipocyte-
specific promoters including fatty acid binding protein-4 (aP2) and adiponectin (AdipoQ) 
have been developed (10). Although both have been used extensively, aP2-Cre activity 
has been detected in the brain, endothelial cells, macrophages, adipocyte progenitors, 
and embryonic tissues (11-13). Thus, the field has shifted to conditional (AdipoQ-Cre) or 
inducible (AdipoQ-CreERT, AdipoChaser) lines (13-15). While useful, Cre-mice must be 
bred to transgenic mice harboring a floxed gene. In some cases, a new floxed line must 
also be generated, which is time consuming, expensive, and involves large cohorts of 
animals. Therefore, more efficient strategies, such as gene transfer, would be beneficial 
to the field. 
 
Step 1: Selection of an Appropriate Vector 
Adipose tissue is very heterogenous, and in many cases, vectors transduce stromal 
vascular cells more efficiently than the adipocytes (7). Thus, a vector must successfully 
navigate the adipose tissue microenvironment to home to the adipocytes. Important 
considerations when selecting a vector should include cargo, tropism, expression profile, 
and immune response (Table 1.1). In this section, we will discuss advancements using 
viral and nonviral vectors for targeting adipocytes. 
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1.1. Viral Vectors 
Different classes of viruses, including lentivirus, adenovirus, and adeno-associated virus 
(AAV), have all been used for gene transfer to adipose tissue. While lentiviruses and 
adenoviruses efficiently transduce adipocytes in vitro, efforts to mediate gene transfer in 
vivo have been less successful. For example, lentiviruses target CD4+ cells and bind to 
the HAdV-C receptor, which is not expressed by adipocytes (16,17). Moreover, 
lentiviruses integrate into the genome leading to insertional mutagenesis (16). While 
several studies using adenovirus have been performed, concerns of its strong 
immunologic response and generation of antibodies against its capsid proteins have 
caused the field to shift to AAV (18-26). AAV is characterized by low immunogenicity, 
epichromosomal expression, and a multitude of serotypes and capsid variants (27).  
Seminal work from the Bosch lab demonstrated that AAV8 and AAV9 preferentially 
transduce white and brown adipocytes with variable transduction efficiencies across 
depots (28). Following systemic delivery, AAV8- and AAV9-GFP were highly expressed 
in the epididymal WAT and interscapular BAT, but marginally expressed in the inguinal, 
retroperitoneal, and mesenteric depots. Interestingly, variability in GFP expression was 
observed across different strains of mice including C57/BL/6J, ICR, ob/ob, and db/db, 
suggesting genetic background may influence transduction efficiency (28,29). To improve 
tropism, recombinant AAVs (rAAV) have been engineered by capsid shuffling to increase 
affinity for adipose tissue. For example, Liu et al. generated rAAVs harboring GFP (Rec2-
GFP) and demonstrated increased adipocyte transduction when compared to the natural 
AAV serotypes 1, 8, and 9 (30). Rec2 vectors were outfitted with Cre-recombinase and 
injected into the inguinal WAT depots of floxed-insulin receptor mice, which led to ~53% 
knockout of the insulin receptor and 50% decrease in inguinal WAT mass. Interestingly, 
these findings are in contrast with AdipoQ-Cre-mediated knockout mice, which develop 
lipodystrophy and metabolic dysfunction characterized by insulin resistance and 
hyperglycemia (31). This might be explained by the fact that Rec2-Cre knockout occurs 
in the adult mouse whereas AdipoQ-Cre causes recombination early in adipocyte 
development.   
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1.2. Nonviral Vectors 
As an alternative approach, nonviral vectors, including organic and inorganic 
nanoparticles, have also been explored for gene transfer to adipose tissue. Nonviral 
nanoscale vectors (<200 nm in diameter) have unique characteristics that make them 
attractive targets for gene transfer and pharmacologic applications. For example, nonviral 
vectors can be functionalized with macromolecules to impart tissue specificity (2,3). 
Efforts to impart adipose specificity have largely focused on conjugating nonviral vectors 
with the peptide sequence CKGGRAKDC (ATS), which binds to the prohibitin receptor on 
the subcutaneous WAT vasculature (32). Hossen et al. formulated ATS-conjugated 
nanoparticles that accumulated in the adipose tissue vasculature of diet-induced obese 
mice (33). In another study, cadmium-based quantum dots functionalized with ATS 
targeted the WAT of obese Wistar rats (34). Whilst the mechanism by which ATS-based 
vectors escape the vasculature to transfect adipocytes remains unknown, research has 
shown that targeting adipose tissue vasculature directly can influence the surrounding 
tissue. For example, Xue et al. developed polymer-based nanoparticles conjugated to 
ATS and loaded with rosiglitazone or prostaglandin E2 analog (35). In treated obese mice, 
WAT vascular density was increased coupled with the upregulation of the BAT markers 
Ucp1, Cidea, and Dio2. Thus, modulation of adipose tissues can be achieved by targeting 
the vasculature. 
Modulation of adipose tissue can also be achieved by targeting the resident 
macrophages to suppress obesity-induced inflammation. In the obese state, endogenous 
low molecular weight hyaluronic acid binds to CD44-expressing cells to trigger 
inflammation and insulin resistance (36). Rho et al. developed hyaluronic acid 
nanoparticles (HA-NPs) to block this pathway and reduce inflammation. HA-NP treated 
obese mice had significant reductions in body weight, glucose tolerance, and insulin 
resistance. Additionally, HA-NPs reduced macrophage infiltration and production of 
inflammatory cytokines in epididymal WAT, likely by outcompeting low molecular weight 
hyaluronic acid for CD44 binding sites. It should be emphasized, however, that HA-NPs 
accumulated predominantly in liver, lungs, and kidneys with only marginal transfection 
observed in the epididymal, subcutaneous, and brown depots. In another study, Ma et al. 
synthesized dextran-conjugates loaded with dexamethasone to reduce inflammation in 
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obese mice (37). Impressively, a single dose reduced the expression of TNFα, IL-6, and 
MCP-1 in the gonadal, perirenal, mesenteric, and subcutaneous depots. Although these 
studies do not involve gene transfer per se, it can be reasoned that genetic cargo can be 
incorporated into these nonviral vectors. In fact, several nonviral nanoscale vectors have 
entered clinical trials for the delivery of siRNA to the vasculature (38). Thus, future 
strategies may involve nonviral-mediated gene transfer to adipocytes, vasculature, or 
macrophages. 
 
1.3. Insights into Targeted Vector Design 
Although both viral and nonviral vectors have been investigated (Figure 1.1), there is no 
consensus method for transducing adipose tissue largely because adipocyte specificity 
remains a major limitation. Therefore, future success will depend on creating targeted 
vectors that enhance tissue tropism and impart tissue-specific transcriptional control. To 
improve tissue tropism, viral envelope glycoproteins have been modified with ligands, 
peptides, and antibodies. Yang et al. created an efficient method that incorporates 
antibodies onto the viral surface and enables the virus to bind to a specific cell type and 
deliver its transgene (39). While this method has not been used to transduce adipocytes 
directly, one can envision the use of adipocyte-specific antibodies against adipocyte-
selective targets such as the amino acid transporter ASC-1 or the brown cell surface 
markers PAT2 or P2RK5 to improve tropism (40). To impart transcriptional control, 
adipose-specific promoters such as AdipoQ or UCP1 can limit off-target transgene 
expression (10,13). It should be noted that the large size of the AdipoQ locus required for 
adipocyte-specificity restricts its use with AAV, although “mini” promoters such as 
mini/UCP1, have been implemented (28). Another strategy employs tissue-specific 
microRNAs targeting posttranscriptional regulatory elements of the transgene. For 
example, Jimenez et al. incorporated multiple microRNAs to prevent transgene 
expression in liver and heart but retained transgene expression in WAT and BAT, 
respectively (28). Thus, targeted vector design that enhances tropism and imparts 
adipose-selective transcriptional control can significantly improve transduction efficiency 
and limit off-target expression. A combination of these strategies will likely emerge as the 
consensus method for gene transfer to adipose tissue. It should be emphasized that 
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careful consideration should be paid to validating transduction efficiency and selectivity, 
either by incorporating a fluorescent probe or by separating the adipocytes from stromal 
vascular cells. We will now turn our attention to the second critical component of delivery: 
route of administration.  
 
Step 2: Optimizing the Route of Administration 
Generally speaking, vector administration can proceed via systemic or local delivery 
(Figure 1.2). Ideally, a vector should transduce every adipocyte across all adipose 
depots, although this goal has never been fully realized. Therefore, selecting a route 
should carefully consider the experimental aims, anatomical location, degree of 
vascularization, and invasiveness in order to optimize transduction efficiency.  
 
2.1. Systemic Delivery via Intravenous Injection 
Intravenous injection capitalizes on the circulatory system’s direct access to all tissues in 
the body. Despite this, the varying degree of vascularization in each adipose depot 
coupled with vector accumulation in reticuloendothelial organs (liver, lung, heart, and 
kidney) limits adipocyte transduction efficiency (1,2,5,6). Successful gene transfer using 
intravenous injection via the tail vein has only been accomplished with adenovirus or AAV, 
however, the field has since shifted exclusively to AAV because of its favorable 
properties. For example, O’Neill et al. intravenously injected AAV2/8 encoding leptin to 
leptin-deficient mice (41). A single injection increased plasma leptin levels to 7% of that 
observed in wild type mice, which led to decreased body weight, food intake, fasting 
insulin levels, and improved glucose tolerance. In another study, rAAV8 vectors 
expressing perilipin A were intravenously injected into mice (42). Treated mice showed 
elevated expression of perilipin A in visceral and subcutaneous WAT and the liver with a 
decrease in serum free fatty acids. Interestingly, however, both of these studies reported 
transgene expression in reticuloendothelial organs despite having transcriptional control 
features, thus highlighting the off-target issues associated with systemic delivery. 
 
2.2. Systemic Delivery via Intraperitoneal Injection 
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Intraperitoneal injection can be rapidly accomplished in conscious animals with minimal 
restraint. Vectors injected intraperitoneally are primarily absorbed into the mesenteric 
vessels that drain into the portal vein and pass through the liver (43). Huang et al. injected 
mice with Rec2-GFP vectors encoding a liver-specific microRNA to prevent off-target 
expression (44). Substantial GFP expression was observed in the epididymal WAT but 
not in other adipose tissues examined nor in reticuloendothelial organs. GFP was 
exchanged for leptin and injected into leptin-deficient mice, which increased lean mass 
and circulating leptin levels, improved glucose tolerance, and reversed hepatic steatosis. 
An important caveat to this study is that vectors transduced only one adipose depot 
despite being injected via a systemic route. 
 
2.3. Systemic Delivery via Oral Gavage 
Enteral delivery through oral gavage is economical, convenient, relatively safe, and 
requires moderate technical skill (43). In a proof of concept study, Huang et al. examined 
the effect of oral gavage on the biodistribution of Rec2 vectors (45). Interestingly, Rec2-
GFP expression was only detected in the BAT, inguinal WAT, and liver, and not in the 
stomach, intestine, heart, kidney, or brain. Rec2-Cre vectors were orally administered to 
floxed-VEGF mice for targeted deletion in BAT. Cold exposure (4°C for 4 hours) led to an 
inability to defend core body temperature, decreased BAT mass, and VEGF protein 
depleted by ~80%. VEGF was then overexpressed using orally administered Rec2, which 
led to an increase in BAT mass and VEGF, UCP1, and CD31 protein levels. The potential 
mechanism by which Rec2 bypasses the gastro-intestinal system to preferentially 
transduce BAT has not been described, however, the authors postulate that the lymphatic 
system may play a role, as Rec2 was detected in the mesenteric adipose depot, which is 
rich in lymph nodes.  
 
2.4. Local Delivery via Intra-Depot Injection 
In contrast to systemic delivery, local delivery is a more targeted approach in which 
vectors are administered directly into a tissue. Although slightly more invasive, time 
consuming, and resource heavy, local delivery via intra-depot injection retains vectors at 
the site of injection, enabling the study of depot-specific function (27,43,46). For adipose 
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tissue, intra-depot injection has proceeded through intra-WAT or intra-BAT injection of 
viral and nonviral vectors. Before attempting intra-depot injection, we recommend 
reviewing references (4-6,27,46) for guidance on how to access these tissues. 
 
2.5. Local Delivery via Intra-WAT Injection 
Mizukami et al. was the first group to optimize intra-WAT injection by administering AAV1-
erythropoietin into the subcutaneous WAT (47). Treated mice showed elevated plasma 
erythropoietin concentration compared to controls. The transduced subcutaneous WAT 
was then surgically removed, causing plasma erythropoietin concentrations to return to 
baseline, indicating that increased circulating erythropoietin was the result of gene 
transfer to WAT specifically. Work from the Bosch lab explored AAV-mediated gene 
transfer to overexpress fibroblast growth factor 21 as a therapeutic strategy for treating 
obesity (48). AAV8 that expressed fibroblast growth factor 21 was administered directly 
into liver, epididymal WAT, or skeletal muscle of obese mice. Interestingly, a single 
injection into the epididymal WAT led to a dose dependent reduction in adipocyte size, 
improvement in insulin sensitivity, and prevention of hepatic steatosis, which was 
comparable to both liver- and skeletal muscle-specific injections. Collectively, these 
studies demonstrate that a single dose of AAV to one adipose depot is sufficient to 
mediate systemic changes to metabolism. 
Lentiviruses have also been used for intra-WAT gene transfer applications. Gnad 
et al. injected a lentivirus expressing the A2A receptor into the inguinal WAT of obese mice 
as an anti-obesity therapy (49). Stimulation of sympathetic drive causes BAT to release 
adenosine, which binds to the A2A receptor to increase energy expenditure. It was 
hypothesized that overexpression of the A2A receptor in inguinal WAT, which has the 
capacity for browning, might have therapeutic potential. Interestingly, lentiviral expression 
of the A2A receptor significantly increased thermogenic and lipogenic markers and led to 
a brown adipocyte-like morphology in the inguinal WAT with increased expression of 
Ucp1, Pgc1α, and Prdm16.  
Only one study has attempted intra-WAT injection of a nonviral vector for gene 
transfer. The Kim lab synthesized an ATS-oligopeptide complex to administer shRNA to 
silence fatty acid binding protein-4 (FABP4) and combat obesity (50). Obese mice were 
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administered the complex via intra-WAT injection on one side of the “abdominal” adipose 
tissue. Strikingly, FABP4 expression was decreased by 70% when compared to the 
contralateral depot. Treated mice also showed significant improvements in insulin 
sensitivity and reduced blood glucose levels. Perhaps the most surprising data are that 
treated mice lost nearly 20% of their body weight following a single administration to one 
WAT depot. While these data are interesting, they also raise several red flags. Firstly, the 
mechanism by which the ATS-oligopeptide-shRNA complex binds to prohibitin on adipose 
tissue vasculature and escapes to transduce the adipocytes has not been explained. 
Secondly, the authors do not report changes in energy balance, lipolysis, inflammation, 
apoptosis, cell death, nor changes in tissue mass in the injected WAT depot, leading us 
to question how silencing FABP4 in one adipose tissue equates to a 20% reduction in 
body weight. This study is also in direct contradiction with previous work that shows 
FABP4 knockdown or knockout in obese mice increases body weight and fat mass 
without changes in glucose homeostasis (51,52). Moreover, it does not report on FABP5 
expression, which is compensatory to loss of FABP4 (53).  
 
2.6. Local Delivery via Intra-BAT Injection 
Similar to intra-WAT injection, AAV has remained the most commonly used vector for 
intra-BAT injection. Two aforementioned studies attempted intra-BAT injection using 
AAVs. Jimenez et al. showed that intra-BAT injection of AAV9 encoding VEGF164 under 
the control of the mini/UCP1 promoter increased vessel density and VEGF164 expression 
specifically in BAT (28). In the second study, Liu et al. administered Rec2-Cre bilaterally 
into the BAT of floxed-insulin receptor mice which decreased BAT size by 50% and 
expression of insulin receptor protein by ~60% (30). Surprisingly, disruption of insulin 
receptor signaling in BAT induced gene expression changes in the hypothalamus, 
highlighting that depot-specific gene transfer can be used to study the interaction between 
adipose tissue and the central nervous system. 
 
The “Gold Standard” Approach for Adipose Tissue Gene Transfer 
Although significant progress has been made using viral and nonviral vectors, the field 
lacks a gold standard approach. Experimental aims will always dictate the selection of a 
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vector and route of administration; however, to guide the reader we propose the following 
set of guidelines: 
 
1. Transcriptionally controlled AAVs currently show the most promise for transducing 
adipocytes in adipose tissues. Researchers should prioritize rAAV, AAV8, or AAV9 
that incorporates an adipose-specific promoter-driven transgene (mini/AdipoQ or 
mini/UCP1), a microRNA to limit transgene expression in off-target tissues, and a 
reporter molecule to validate transduction efficiency. 
 
2. To maximize adipocyte transduction efficiency and limit accumulation in off-target 
tissues, vectors should be administered locally via intra-WAT or intra-BAT 
injection. 
 
3. To validate your experiment, follow the gold standard approach outlined in Figure 
1.3. For validating adipocyte transduction, vectors should be outfitted with 
fluorescent probes or administered to reporter lines such as the mT/mG mouse 
(54). Successful transduction is characterized by a fluorescent “halo” surrounding 
the adipocyte. As adipocytes represent only a small fraction of the total cells in 
adipose tissue, they should be separated from stromal vascular cells by buoyant-
density centrifugation, and both fractions analyzed for transduction.  
 
While we have focused on transducing adipocytes, it should be noted that targeting the 
vasculature or resident macrophages is an alternative strategy for manipulating adipose 
tissues. This is particularly true for nonviral vectors, although continued research is 
required.  
 
II. CRISPR/CAS9: THE FUTURE OF ADIPOSE TISSUE GENE TRANSFER 
 
CRISPR/Cas9 Gene Transfer in Adipose Tissue 
With the emergence of powerful gene editing technologies like CRISPR/Cas9, 
researchers can modify virtually any region of the genome. CRISPR/Cas9 is composed 
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of two components: the Cas9 endonuclease, and a programmable single guide RNA 
(sgRNA) that directs Cas9 where to create double-strand breaks in genomic DNA (55). 
CRISPR/Cas9 is thus easily amendable to viral or nonviral gene transfer as its constitutive 
parts can be genetically encoded. Despite the adoption of CRISPR/Cas9 gene transfer 
to a variety of tissues (56-59), only one study reports its use in adipose tissue (60). We 
recommend caution, however, as this study uses the ATS-oligopeptide complex 
described above for CRISPR-interference silencing of FABP4 (50,60). 
Two studies have recently reported on in vitro delivery of CRISPR/Cas9 to cultured 
adipocyte precursors. The Czech lab successfully transfected isolated primary 
preadipocytes with nonviral vectors loaded with Cas9 protein and a sgRNA targeted to 
Nrip1 (61). Treated cells showed a mutation frequency of 43.8% in the Nrip1 locus 
coupled with increased expression of the brown-like genes Ucp1, Cidea, Pgc1α, Prdm16, 
and Cpt1b. Importantly, no off-target mutations were detected and CRISPR/Cas9 did not 
affect the capacity to differentiate. In a second study, Kamble et al. electroporated human 
preadipocytes with a ribonucleoprotein complex of Cas9 and a sgRNA targeted to Pparg 
or Fkbp5 (62). Impressively, treated cells achieved 90% efficiency and did not require 
selection or clonal isolation of edited cells. While these studies demonstrate in vitro proof 
of principle, the field has yet to report successful in vivo gene transfer of CRISPR/Cas9 
to adipose tissue. 
 
The Future of Adipose Tissue Genome Editing 
CRISPR/Cas9 gene transfer to adipose tissue is in its infancy, however, we can gain 
several insights from its use in other tissues and apply these to the gold standard 
approach. For example, CRISPR/Cas9 gene transfer can proceed via exogenous 
expression or a combination of exogenous/endogenous expression of its components. In 
the exogenous method, both Cas9 and sgRNA are delivered via a vector. In the 
exogenous/endogenous method, the sgRNA is delivered to a Cas9-expressing mouse 
line (63,64). Thus, rAAVs can be encoded with one or multiple sgRNAs and administered 
locally to AdipoQ-Cre dependent Cas9 mice to enable spatial control (63). Cas9 
expression can also be temporally regulated using a doxycycline-inducible line developed 
by Dow and Fisher (64). Ultimately, CRISPR/Cas9 has immense potential for elucidating 
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the underlying mechanisms to a myriad of metabolic diseases. For instance, future 
application of CRISPR/Cas9 might entail homology-directed repair to correct single 
nucleotide polymorphisms associated with aberrant metabolism (65). Particular focus 
should be paid to integrating CRISPR/Cas9 with well-established gene transfer 
techniques such as AAV and Cre-Lox mouse models (63,64). Moreover, we also 
recommend a strong adherence to the gold standard approach to validate transduction 
efficiency. With these powerful technologies in hand, the field of adipose tissue biology is 
poised to enter a new era of research. 
Indeed, selectively targeting adipocytes for CRISPR/Cas9 somatic mutagenesis 
can significantly improve the way in which we study adipose tissues in vivo. However, 
current delivery strategies must first be optimized and validated before such technologies 
can be applied. Thus, my doctoral work described in the following chapters will provide a 
framework by which viral and nonviral vectors were tested for adipocyte specificity in vivo 
and then applied to enable CRISPR/Cas9 inducible knockout in BAT. As such, I 
developed an efficient methodology to significantly improve the way in which we study 





Table 1.1. Viral and nonviral vector properties and affinity for adipose tissue. Viral 
vectors including lentivirus, adenovirus, and AAV can transduce adipose tissues as well 
as cultured preadipocytes and adipocytes. Of the classes of viruses, AAV has been the 
most widely used owing to its tropism, expression profile, and low immune response. 
Nonviral vectors including organic and inorganic nanoparticles have been shown to 
transfect adipose tissue vasculature and macrophages in addition to cultured 
preadipocytes. Further research is required to confirm nonviral transfection of adipocytes 





Figure 1.1. Viral and nonviral vectors have been used to target adipose tissue. 
Adipose tissue is very heterogeneous, and adipocytes represent a minority of cells in 
adipose tissue. Thus, a vector must successfully navigate through a variety of cell types 
to home to the target cell. Viral vectors have been used to transduce adipocytes. Nonviral 
vectors have been used to transfect adipose tissue vasculature and resident 





Figure 1.2. Adipocyte transduction efficiency is highly dependent upon route of 
administration. Gene transfer to adipose tissue has proceeded through both systemic 
and local delivery of viral and nonviral vectors. Systemic delivery via intravenous injection, 
intraperitoneal injection, or oral gavage accumulates largely in liver and 
reticuloendothelial organs even when vectors are outfitted with transcriptional control 
features. By contrast, local delivery via intra-WAT or intra-BAT injection retains the vector 







Figure 1.3. The “gold standard” approach for validation of adipose tissue gene 
transfer. For maximal transduction efficiency and minimal accumulation in off-target 
tissues, vectors (preferably AAV) should be administered locally through intradepot 
injection. The most commonly targeted adipose depots are the interscapular BAT, the 
posterior subcutaneous WAT, and the gonadal WAT. For validation of successful gene 
transfer, AAV vectors should be outfitted with a reporter such as a fluorescent protein 
and/or Cre recombinase. Dissected tissues should be imaged or fixed to confirm 
adipocyte transduction. In this example, mT/mG mice were administered AAV8-Cre via 
local injection into the posterior subcutaneous WAT. GFP expression is indicative of 
successful gene transfer and expression of Cre within the adipocytes. Adipose tissue 
should then be digest and fractionated to separate adipocytes from stromal vascular cells. 
The isolated adipocytes and stromal vascular cells can then be analyzed for specificity of 
transgene expression or cultured for further analyses.   
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Transduction of adipose tissues is notoriously difficult as adipocytes are located 
throughout the body in distinct depots. Thus, we sought to identify strategies to maximize 
transduction of adipose tissues using viral and nonviral vectors. We formulated a library 
of lipid nanoparticles (LNPs) encapsulating messenger RNA (mRNA) or plasmid DNA 
(pDNA) using two microfluidics devices. Physical properties were fine-tuned by altering 
the genetic cargo, lipid molarity, nitrogen/phosphate (N/P) ratio, and flow rate. Lead LNP 
formulations demonstrated transfection without cytotoxicity in vitro. Additionally, we 
explored LNP biodistribution kinetics in vivo and found that genetic cargo strongly 
influenced biodistribution. pDNA loaded LNPs showed intrinsic affinity for white adipose 
tissues (WATs) but also transduced reticuloendothelial organs, indicating that additional 
work is required to impart increased adipose tissue tropism. While we were unable to 
demonstrate uptake by adipocytes per se, we show for the first time that systemic delivery 
of LNPs can be used to transfect adipose tissues. We then focused our attention to 
optimize adipose transduction using adeno-associated virus 8 (AAV8) by testing systemic 
and local routes of administration. Systemic delivery by intravenous injection and local 
delivery by intra-WAT injection did not effectively transduce adipose tissues. Interestingly, 
local delivery by intra-BAT injection led to robust transduction of brown adipocytes within 
the interscapular BAT. Thus, we propose intra-BAT injection as a delivery strategy to 
maximize brown adipocyte transduction. This may enable the use of AAV8 to administer 






Targeted delivery of genetic materials to adipocytes represents a major hurdle for the 
field of adipose tissue research. This is largely because adipocytes are found throughout 
the body in unique depots and each depot is functionally distinct from others, leading 
some to propose that each should be classified as a separate “mini-organ” (1). Differential 
gene expression, variation in cellular composition, degree of vascularization, and 
neurological and/or hormonal factors also contribute to regional differences in adipose 
tissues (1-3). Moreover, adipocytes comprise a minority of the total cell population in each 
depot, which is predominantly populated by stromal vascular cells, macrophages, 
preadipocytes, and stem cells (4). Collectively, these characteristics complicate targeting 
adipocytes in vivo. Efficient transfection of adipocytes in vitro also remains challenging, 
as immortalized murine and human cell lines including 3T3-L1, BCF-1, HB2, human 
adipose-derived stem cells, and Simpson-Golabi-Behmel syndrome cells, are largely 
resistant to traditional transfection and electroporation techniques as compared to other 
cell types (5-7). In many ways, an inability to effectively transduce adipose tissues has 
caused the field to lag in implementing more advanced technologies such as 
CRISPR/Cas9 inducible gene knockout towards understanding adipose tissues. 
Currently, the use of recombinant adeno-associated viruses (AAVs) is considered 
the “gold standard” for transducing adipocytes in vivo (8-10).  In contrast to lentiviruses 
and adenoviruses, AAV remains episomal and does not elicit a strong immune response, 
which coupled with its multitude of capsid serotypes, makes it a favorable vector for gene 
transfer applications (11). Several studies have identified that AAV serotypes 8 and 9 
show high affinity for adipose tissues (12-20). Collectively, these studies have helped 
shape the current “gold standard” approach for transducing adipose tissues, which posits 
that local delivery of recombinant AAV serotype 8 or 9 maximizes adipocyte transduction 
in white (WAT) and brown (BAT) adipose tissues (9). Although AAV8 and AAV9 have 
been used to transduce individual adipose depots, whole-body transduction of all adipose 
tissues has not been accomplished. Neither local delivery nor systemic delivery via 
intravenous injection, intraperitoneal injection, nor oral gavage have resulted in total 
transduction of all adipose depots across the body (9). For instance, following systemic 
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delivery of AAV8 or AAV9, Jimenez et al. reported broad variations in transduction 
efficiency across inguinal, retroperitoneal, mesenteric, and epididymal WAT as well as 
interscapular BAT (13). Moreover, variations in transduction efficiency were also 
observed across different genetic strains of mice (13). Despite the affinity of AAV8 and 
AAV9 for adipose tissue, systemic delivery primarily results in significant vector 
accumulation in liver. O’Neill and colleagues demonstrated that systemic delivery of AAV8 
resulted in >200-fold more copies of AAV DNA in liver than in BAT, gonadal, or omental 
WATs (14). Thus, identifying alternative delivery strategies may be necessary to achieve 
whole-body adipose tissue transduction and limit accumulation in liver.  
Nanoparticles (NPs) are an alternative delivery strategy that have recently been 
employed to target adipose tissues. Broadly speaking, NPs are nonviral vectors between 
1-1000 nm in diameter that can facilitate the delivery of genetic and/or therapeutic 
cargoes to tissues of interest (21). NPs are classified according to the materials with which 
they are composed. For example, NPs can be categorized as polymeric (polymersomes, 
dendrimers, nanospheres), inorganic (quantum dots, iron oxide NPs, gold NPs), or lipid-
based (liposomes, lipid NPs, emulsions) (22). Unlike viral vectors, NPs are synthetically 
produced, meaning particle architecture and composition can be fine-tuned for specific 
applications. A growing body of literature has begun to explore NPs for targeting adipose 
tissue (23-30). For instance, polymeric NPs have been functionalized to target WAT 
vasculature (24,25,28,29). Polymeric NPs have also been used to reduce inflammation 
in obese mice by binding to adipose tissue resident macrophages (26,27). Peptide-
functionalized quantum dots have also been developed to image WAT vasculature in 
obese Wistar rats (30). However, while these studies demonstrate that NPs can be used 
to target WAT vasculature or resident macrophages, they ultimately fail to transfect 
adipocytes. In fact, the majority of transfection is observed in off-target tissues. Ma et al. 
reported accumulation of NPs predominantly in liver, lung, and kidney, with marginal 
transfection observed in epididymal, subcutaneous, and brown adipose tissues (27). 
Therefore, continued research is required to i.) demonstrate NP uptake by adipocytes, 
and ii.) prevent uptake in off-target tissues. To accomplish this, testing different classes 
of NPs, such as lipid-based NPs, is warranted.  
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Lipid nanoparticles (LNPs) represent a mature class of NP that have transformed 
the world as of recent by facilitating the delivery of mRNA for vaccination against SARS-
CoV-2 (31). Relative to other NP classes, LNPs are significantly easier to manufacture 
and have a highly efficient encapsulation process to enable loading with oligonucleotides 
or plasmid DNA (pDNA) for gene transfer applications (32). LNPs are typically composed 
of a cationic ionizable lipid, a structural or “helper” lipid, cholesterol (Chol), and 
polyethyleneglycol (PEG) (33). A combination of these lipid specifies causes the 
destabilization of the endosomal membrane following cellular uptake and facilitates 
cytoplasmic release of the genetic cargo (34). Recently, LNPs have shown promise in 
targeting adipocytes in vitro. The Pharmaceutical Sciences iMed Biotech Unit at 
AstraZeneca utilized LNPs containing human erythropoietin mRNA and demonstrated 
gene transfer to cultured primary human adipocytes (35). To this point, however, the 
affinity of LNPs for adipose tissues has not been explored in vivo. 
Thus, we formulated LNPs and tested their affinity for adipose tissues. We 
generated a library of LNPs using two different microfluidic devices to rapidly mix the 
cationic ionizable lipid DLin-MC3-DMA (MC3), distearoylphosphatidylcholine (DSPC), 
Chol, and PEG with pDNA or mRNA. LNPs ranged in size from 80-267 nm in diameter 
depending on the genetic cargo, lipid molarity, nitrogen/phosphate (N/P) ratio, and 
microfluidics device used to formulate the LNP. After assessing LNPs in vitro, we selected 
two formulations, one from each microfluidics device, for in vivo biodistribution studies. 
Interestingly, we found that LNP biodistribution following intravenous injection was 
strongly influenced by genetic cargo. IVIS imaging showed LNPs loaded with mRNA 
(mRNA-LNPs) mainly localized to liver and expression was maximal between 6-24 hours. 
By contrast, LNPs loaded with pDNA (pDNA-LNPs) were more broadly distributed across 
tissues, especially in WATs, and expression was maximal between 24-48 hours. Despite 
an affinity of pDNA-LNPs for adipose tissues, pDNA-LNPs were also detected in liver, 
spleen, kidney, lung, and heart, highlighting that systemic delivery of LNPs leads to off-
target transfection. While we were unable to confirm that LNPs are taken up specifically 
by adipocytes, we show that pDNA-LNPs are intrinsically adipophilic, suggesting that 
conjugation with adipocyte-specific moieties may enhance tissue tropism.  
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We then shifted our focus towards applying AAV8 to transduce adipose tissues. 
Specifically, we explored how route of administration influences adipose tissue 
transduction. We found that local injection specifically to the interscapular BAT leads to 
robust transduction with minimal leak to liver. Interestingly, neither local delivery to the 
posterior subcutaneous WAT nor systemic delivery via intravenous injection resulted in 
sufficient transduction of WATs or BAT. Thus, we show that local injection of AAV8 to 
BAT facilitates efficient gene transfer and therefore may potentially enable the use of 
CRISPR/Cas9 inducible gene knockout as a tool to study adipose tissues in vivo. 
 
RESULTS 
Microfluidic mixing formulates LNPs with different physical properties 
LNPs are typically formulated via the rapid mixing of nucleic acids dissolved in water 
(aqueous phase) and lipids dissolved in ethanol (lipid phase) (Figure 2.1a). Millisecond 
mixing of the lipid and aqueous phase drives the formation of an inverted micelle that 
encapsulates the nucleic acid and prevents aggregation to produce a monodisperse LNP 
suspension (32,36). We used two microfluidics devices to produce LNPs: the 
NanoAssemblr Benchtop and the Hamilton MicroLab Star. Both devices rely upon rapid 
mixing using a staggered herringbone microfluidic channel. Herringbone structures 
induce chaotic advection of laminar streams, which rapidly mixes the aqueous and lipid 
phases to increase polarity, leading to LNP precipitation (36). This process enables 
“bottom-up” synthesis of LNPs by spontaneous self-assembly. We followed the protocol 
established by Belliveau et al. to formulate LNPs containing MC3:DSPC:Chol:PEG 
(50:10:38.5:1.5) and loaded LNPs with pDNA encoding mCherry at a ratio of 1:3 
(lipid:pDNA) (37). In total, we formulated four LNP formulations using the NanoAssemblr 
(N1, N2, N3, N4), and four LNP formulations using the Hamilton (H1, H2, H3, H4) (Figure 
2.1b-c, Table 2.1). We varied lipid molarity, N/P ratio, mixing speed, and PEG content 
which influenced both the diameter and polydispersity index (ĐM) of the LNPs (Figure 
2.1b-c, Table 2.1). The N/P ratio is the ratio of positively charged amines (MC3) to 
negatively charged nucleic acid phosphates (pDNA). The N/P ratio influences LNP 
surface charge, size, and stability, with higher N/P ratios enhancing intracellular delivery 
(38). In general, a net positive N/P ratio has been reported to improve LNP efficacy for 
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gene transfer applications; however, too high of a positive ratio can be cytotoxic (39). Our 
pDNA-LNPs had a N/P ratio between 6.2-12.4, which is in line with previously established 
systems (Table 2.1) (33). We measured LNP size using dynamic light scattering, which 
calculates the hydrodynamic diameter by measuring the speed of LNPs dispersed in 







Where 𝐷!	= translational diffusion coefficient [m2/s], 𝑘" = Boltzmann constant [m2kg/Ks2],	
T	= temperature [K], 𝜂	= viscosity [Pa∙s], and	𝐷#	= hydrodynamic radius [m] (40). pDNA-
LNPs formulated using the NanoAssemblr were smaller (91-127 nm) compared to LNPs 
generated using the Hamilton (170-267 nm) (Figure 2.1b). This is likely caused by 
differences in the microfluidics channels between the two devices. Dynamic light 







Where Đ$ = polydispersity index, 𝑀% = weight average molecular weight, and 𝑀& = 
number average molecular weight (40). All pDNA-LNPs formulated by the NanoAssemblr, 
or Hamilton were homogenous in size and distribution (Figure 2.1c).  
 
LNPs transfect cells in vitro and are non-cytotoxic 
Positively charged LNPs interact with negatively charged cell surfaces and are taken up 
via endocytosis (Figure 2.2a) (39). Once inside an endosome, the cationic MC3 lipid 
destabilizes the membrane by forming ion pairs with anionic phospholipids in the 
endosomal membrane, causing the membrane to adopt a non-bilayer lipid structure and 
allowing the pDNA to escape into the cytosol (Figure 2.2a) (34). To test if the 
NanoAssemblr and Hamilton LNPs followed this mechanism, we transfected B16-F10 
cells using LNPs loaded with mCherry pDNA. We selected two LNP formulations–one 
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formulated using the NanoAssemblr (N2-LNP) and the other using the Hamilton (H2-
LNP)– based on size, N/P ratio, and encapsulation efficiency (Figure 2.1b-c, Table 2.1, 
Figure 2.2b). While a multitude of studies have shown efficient delivery of siRNA or 
mRNA using LNPs, much less is known about their ability to deliver pDNA. This stems 
from differences in size and charge of pDNA compared to smaller oligonucleotide 
cargoes, which necessitates modification of lipid and N/P charge ratios to maximize 
cellular uptake (33). Both N2-LNPs and H2-LNPs had a N/P ratio of 9.3 (Table 2.1). 
Based on this, we were able to estimate that mCherry pDNA (5.3 kb; 5.3 × 103 total 
negative charges) corresponds to 4.9 × 104 amino-lipids per pDNA, which reflects a 
condensed structure of the encapsulated pDNA (33).  
Next, N2-LNPs and H2-LNPs were transfected into murine B16-F10 cells and 
mCherry expression was monitored in real-time (Figure 2.2c). We dosed LNPs at 
concentrations of 1 μg/mL, 3 μg/mL, and 6 μg/mL, and used Lipofectamine 3000 as a 
positive control to assess transfection efficiency. We observed a dose-dependent 
increase in mCherry expression for both N2-LNPs and H2-LNPs (Figure 2.2c-d). N2-
LNPs were more efficient, with maximal transfection in 33% of cells observed at 72 hours 
compared to H2-LNPs, which had maximal transfection of 11% at 84 hours (Figure 2.2c). 
This is likely due to the differences in size between the two LNPs, as smaller LNP systems 
have improved transfection potency (Figure 2.1b, Table 2.1) (33,41). Additionally, the 
percent encapsulated pDNA was higher in the N2-LNPs compared to H2-LNPs (92% and 
68%), which might also account for the differences in mCherry expression (Figure 2.2b). 
Although Lipofectamine 3000 showed maximal transfection at 30 hours and transfected 
~40% of cells, it was also much harsher relative to both N2-LNPs and H2-LNPs when 
used to dose an equal amount of pDNA (Figure 2.2e). Collectively, these data show that 
N2-LNPs and H2-LNPs can deliver pDNA to cells in vitro and are non-cytotoxic.  
 
Systemic delivery of mRNA-LNPs primary transfects liver but not adipose tissues 
LNPs have been used extensively for the delivery of mRNA both experimentally in animal 
models and clinically in humans, however, their affinity for adipose tissues following 
systemic delivery has not been reported (31,32,42,43). Thus, we sought to characterize 
the biodistribution kinetics of N2-LNPs and H2-LNPs loaded with luciferase mRNA. LNPs 
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were formulated as described previously, with the lipid to nucleotide mass ratio adjusted 
to 20:1 to account for the mRNA cargo. As a result, mRNA-LNPs were smaller compared 
to pDNA-LNPs; N2-LNPs were 80 nm in diameter while H2-LNPs were 176 nm in 
diameter, respectively (Figure 2.3a). To assess biodistribution kinetics, mice were 
injected with 0.25 mg/kg N2-LNP or H2-LNP by intravenous injection via the tail vein and 
imaged at 6 and 24 hours post injection (n = 3 mice) (Figure 2.3a). Prior to imaging, mice 
were administered 150 mg/kg of D-luciferin by intraperitoneal injection. Maximal 
luminescence was detected at 6 hours post injection for both N2-LNPs and H2-LNPs 
(Figure 2.3a). Interestingly, H2-LNPs showed a higher average radiance compared to 
N2-LNPs, despite having a larger diameter (Figure 2.3a). IVIS imaging suggested both 
N2-LNPs and H2-LNPs localized to liver at both 6 and 24 hours, with decreased 
luminescence detected at 24 hours post injection (data not shown). To further assess 
tissue biodistribution, mice were sacrificed at 24 hours and tissues were imaged for 
luciferase expression. We observed robust luminescence in liver for both N2-LNPs and 
H2-LNPs and mild signal in posterior subcutaneous WAT (psWAT) and spleen, but no 
indication of sufficient transfection of BAT or epididymal WAT (eWAT) (Figure 2.3b). 
These results demonstrate that mRNA-LNPs do not show inherent affinity for adipose 
tissues.  
 
pDNA-LNPs localize to adipose tissues and reticuloendothelial organs following 
systemic delivery 
We next sought to explore the biodistribution kinetics of LNPs loaded with luciferase 
pDNA to see if altering the genetic cargo influenced transfection efficiency in vivo. LNPs 
were formulated as described above, however, the ratio of lipid to pDNA was adjusted to 
33:1 to compensate for the larger genetic cargo. Relative to mRNA-LNPs, pDNA-LNPs 
were larger in size; N2-LNPs were 132 nm in diameter and H2-LNPs were 199 nm in 
diameter, respectively (Figure 2.4a). Mice were injected with 0.25 mg/kg N2-LNP or H2-
LNP by intravenous injection via the tail vein and were administered 150 mg/kg of D-
luciferin by intraperitoneal injection prior to imaging (n = 3). Luminescence was not 
detected at 6 or 24 hours post injection (data not shown), but robust signal was observed 
throughout the abdomen after 48 hours (Figure 2.4a). The delayed onset of luciferase 
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expression arises because pDNA must first be transcribed to mRNA before it is translated 
to luciferase protein. There was no difference in transfection efficiency between N2-LNPs 
and H2-LNPs as measured by average radiance (Figure 2.4a). After 48 hours, mice were 
sacrificed, and tissues were imaged to characterize biodistribution kinetics. Interestingly, 
we observed pronounced luminescence signal in the psWAT and eWAT with reduced 
signal detected in liver (Figure 2.4b). N2-LNPs and H2-LNPs also localized to BAT, 
spleen, kidney, lung, and heart.   
The mechanism by which pDNA-LNPs and not mRNA-LNPs localize to WATs 
remains to be determined. Following systemic delivery into the bloodstream, LNPs 
become opsonized, a process by which nonspecific proteins coat the surface of the LNP 
(44). Physical properties, such as charge, size, and surface composition influence the 
protein “corona” that forms around the LNP. The proteins that bind to the surface of the 
LNP can have important consequences on its biodistribution kinetics. For instance, 
opsonized LNPs can be taken up by Kupffer cells in the liver or by macrophages in the 
spleen, as well as by other phagocytic cells of the reticuloendothelial system for 
degradation (44). In general, opsonization of LNPs is governed by hydrophobic and 
electrostatic interactions of proteins with the surface of the LNP (45,46). Given the 
differences in size of mRNA and pDNA cargoes, we had to adjust the ratio of lipid to 
nucleic acid to formulate mRNA-LNPs and pDNA-LNPs. As a result, the surface charge 
and LNP size was different. Lundqvist et al. showed that NP size and charge strongly 
influence the protein corona (47). Thus, although the lipid species utilized to formulate 
mRNA-LNPs and pDNA-LNPs were the same, the different physical properties of each 
likely account for changes in biodistribution kinetics. 
While we did observe luminescence in psWAT, eWAT, and minor signal in BAT, 
we were unable to confirm if pDNA-LNPs were taken up by adipocytes or by stromal 
vascular cells (Figure 2.4b). It is possible that LNPs home to adipose tissues but remain 
trapped in the adipose tissue vasculature, or are phagocytosed by resident macrophages 
which take up the opsonin-coated LNPs (47). Future work will therefore need to validate 
LNP affinity for adipocytes, perhaps by administering LNPs loaded with Cre-recombinase 
pDNA to mT/mG reporter mice (48). Moreover, significant work is required to promote 
transfection of all adipose tissues throughout the body and to reduce LNP accumulation 
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in off-target organs. Thus, while these initial results using LNPs show promise, they 
unfortunately fail to resolve the issue of sufficiently targeting all adipose tissues. 
Therefore, we shifted our focus back to optimizing the current gold standard approach for 
transducing adipose tissues: adeno-associated virus 8 (AAV8).  
 
Route of administration strongly influences AAV8 transduction efficiency of 
adipose tissues 
AAV8 remains the gold standard for transducing adipose tissues, however, the broad 
variability in transduction efficiency and lack of consistency in assessing degree of 
transduction that have been reported in the literature call into question its true affinity for 
adipose tissues (8-10). Careful assessment of the literature has shown that route of 
administration plays an important role in AAV8 biodistribution (9). In order to assess how 
route of administration influences adipose tissue transduction, we administered AAV8-
mCherry to mice via three different routes of administration: systemic delivery by 
intravenous injection, local delivery by intra-BAT injection, and local delivery by intra-WAT 
injection. 
Mice were administered 100 μL 1012 vg/mL AAV8-mCherry according to previously 
established protocols (13,49). Intravenous injection was accomplished via the tail vein, 
whereas intra-BAT and intra-WAT injections were performed by making a 1-2 cm incision 
and peeling back the skin to visualize the interscapular BAT or the posterior 
subcutaneous WAT and injecting AAV8-mCherry directly into the depot (Figure 2.5a-c) 
(13,49). Mice were sacrificed 14 days after injection and tissues were analyzed for AAV8 
biodistribution and adipocyte transduction efficiency. Quantitative PCR (qPCR) indicated 
that mCherry mRNA tissue expression was influenced entirely by route of administration 
(Figure 2.5a-c). Intravenous injection resulted in pronounced mCherry expression in liver, 
and confocal microscopy confirmed transduction was liver-specific with very few 
adipocytes transduced in BAT and psWAT (Figure 2.5a, 2.5d). By contrast, local delivery 
via intra-BAT injection led to robust mCherry signal in BAT and reduced signal detected 
in liver (Figure 2.5b, 2.5d). We did not detect mCherry expression in WATs using intra-
BAT injection. Interestingly, local delivery via intra-WAT injection led to mild transduction 
of both psWAT and BAT, with robust mCherry expression detected in liver (Figure 2.5c, 
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2.5d). We did not observe transduction of eWAT in any route tested (Figure 2.5a-d). 
Thus, we unfortunately were unable to transduce all adipose tissues regardless of the 
route by which AAV8-mCherry was administered. We did however notice an apparent 
affinity of AAV8 for BAT, as each route showed positive transduction of brown adipocytes 
in the interscapular depot (Figure 2.5a-d). BAT is a unique adipose tissue involved in 
adaptive thermogenesis and in rodents is found predominantly in an easily accessible 
interscapular location (2,3,48,50). BAT also has important endocrine functions and in 
humans is inversely associated with body mass index (51,52). Thus, based on these 
results, we reframed our approach to focus on applying AAV8 to facilitate CRISPR/Cas9 
for use in adipose tissue. In chapter 3, we demonstrate for the first time that local injection 
of AAV8 enables CRISPR/Cas9 inducible gene knockout in BAT. 
 
DISCUSSION 
An emerging trend to model disease or study gene function has focused on the delivery 
of CRISPR/Cas9 to tissues of interest. Viral transduction, nonviral transfection, and/or 
combination with transgenic Cas9 animal models has enabled use of CRISPR/Cas9 in 
tissues such as liver, heart, skeletal muscle, and the central nervous system for somatic 
gene editing (53,54). As highlighted above, targeting adipose tissues using viral or 
nonviral approaches has proved a major challenge for the field and has therefore 
prevented the delivery of CRISPR/Cas9 to improve our understanding of these 
metabolically important organs. In this work we report preliminary results on the use of 
LNPs to target adipose tissues in vivo. While we were unable to show that pDNA-LNPs 
directly transfect adipocytes per se, we provide evidence that pDNA-LNPs have inherent 
tropism to adipose tissues, suggesting that further optimization can lead to robust 
adipocyte transduction and limited uptake in off-target organs. We also show that local 
delivery of AAV8 to BAT yields sufficient transduction of brown adipocytes with minimal 
leak to liver. Ultimately, we anticipate that future work will build off these preliminary data 




In this study, two microfluidics devices were used to formulate a library of LNPs 
encapsulating pDNA via the rapid mixing of aqueous and lipid phases. This generated 
LNPs ranging in size from 80-267 nm in diameter. We found that LNP size was largely 
determined by the microfluidic device used to formulate the LNPs, with formulations 
generated using the NanoAssemblr having a smaller size than those generated using the 
Hamilton. The size of LNPs was also influenced by the PEG content, as formulations N3-
LNP and H3-LNP, in which the PEG molarity was increased to 2.5 mM and Chol 
decreased to 37.5 mM, were 91 nm and 182 nm in diameter, respectively. PEG resides 
in the outer monolayer of the LNP and allows higher surface-to-volume ratios that results 
in smaller limit sizes as the PEG content is increased (37,55). PEG also decreases the 
adsorption of serum proteins involved in the opsonization process, which can improve 
delivery in vivo (56). While PEG can impart beneficial physical properties to LNPs, 
multiple studies have reported unexpected immunological responses to PEG-conjugated 
NPs (57). Therefore, future formulations should consider these factors to decrease LNP 
size, shield LNPs from opsonization, and prevent immunological responses.  
LNPs used for in vitro and in vivo studies were all composed of the same four lipid 
species: MC3:DSPC:Chol:PEG. We chose MC3 as the cationic lipid because it has been 
used extensively for efficient in vivo delivery of nucleic acids and is non-cytotoxic 
(33,37,58). MC3 has a pKa of 6.4, which is low enough that the LNP is tolerated at 
physiological pH but high enough that it is ionized at endosomal pH to disrupt the 
endosomal membrane (59). Several other cationic lipids have been used to formulate 
LNPs. For example, the amino-lipids DLin-KC2-DMA, DLinDMA, DLinDAP, DOTAP, and 
DSGLA have all been used (60-62). Moreover, a variety of helper lipids have also been 
tested. For example, Kulkarni et al. demonstrated that LNPs containing the helper lipids 
DOPE or DOPC showed improved transfection in vivo compared to LNPs containing 
DSPC (33). Thus, altering the lipid composition of LNPs may lead to improved affinity for 
adipose tissue. Additionally, conjugating LNPs with adipophilic moieties may improve 
transduction. For instance, the peptide sequence CKGGRAKDC, which binds to prohibitin 
in WAT vasculature, has been shown to enhance homing of NPs to adipose tissues (28-
30). Future LNP formulations will thus require careful design using different combinations 
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of cationic lipids, helper lipids, PEG content, and peptide sequences to impart specificity 
and prevent off-target accumulation.  
Interestingly, we observed differences in the uptake kinetics of LNPs in vitro and 
in vivo. For instance, N2-LNPs vastly outperformed H2-LNPs in transfecting cells in 
culture, however, in vivo, both N2-LNPs and H2-LNPs loaded with pDNA transfected 
tissues to a similar degree. In fact, in vitro experiments are typically poor indicators for in 
vivo bioavailability of NPs. This is because in vitro systems lack the complexities 
associated with in vivo systems, in which a number of variables affect transfection 
efficiency (63). Whitehead et al. reported that using primary hepatocytes to test LNP 
systems in vitro had the best correlations with in vivo studies in which LNPs were targeted 
to liver, suggesting that when possible, primary cell lines should be used to most closely 
model in vivo kinetics (63). In our studies, we performed in vitro studies using B16-F10 
cancer cells, as well as immortalized 3T3-L1 cells. While we did observe transfection of 
B16-F10 cells, we were unsuccessful in transfecting preadipocyte and differentiated 3T3-
L1s (data not shown). For future studies, however, transfecting primary preadipocytes 
and differentiated adipocytes should be attempted, and results compared to in vivo 
studies to determine if corollaries exist. Such research can be used to significantly 
enhance LNP affinity for adipose tissues. 
Although we were able to demonstrate transfection of WATs in vivo, we were 
unable to determine if LNPs were taken-up by adipocytes or stromal vascular cells. As 
such, we shifted our attention back to the current gold standard, AAV8. We showed that 
local delivery of AAV8 led to robust transduction of brown adipocytes within BAT, and 
therefore decided to focus on targeting BAT for CRISPR/Cas9 inducible gene knockout. 
To ultimately realize CRISPR/Cas9 inducible gene knockout in adipose tissues, however, 
significant work is required. First, packaging limitations of AAV prevent the incorporation 
of both Cas9 and a single guide RNA (sgRNA) (9,10). To overcome this, transgenic Cas9 
expressing mice should therefore be considered (64). Second, because AAV8 also 
transduces liver when administered by local injection to the interscapular BAT, 
transcriptional control features should be utilized to prevent off-target mutations in non-
target tissues. Thus, we hope that lessons from this study provide a foundational context 
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for future studies that seek to apply LNPs or AAV8 to induce CRISPR/Cas9 gene 




MATERIALS AND METHODS 
LNP Formulation and Characterization 
LNPs were formulated by following the protocol established by Belliveau et al. (37). For 
in vitro studies, LNPs were loaded with pDNA containing mCherry (#87916, Addgene, 
Watertown, MA, USA). pDNA was prepared in 25 mM citrate buffer at pH 4.0 to create 
the aqueous phase. The lipid phase was prepared by dissolving DLin-MC3-DMA (545-
70-2, AstraZeneca R&D Charnwood, Loughborough, UK), distearoylphosphatidylcholine, 
cholesterol, and polyethyleneglycol (AstraZeneca Granta Park, Cambridge, UK) in 100% 
ethanol at a molar ratio of 50:10:38.5:1.5. The aqueous and lipid phases were rapidly 
mixed using two microfluidic devices, the NanoAssemblr Benchtop (Precision 
Nanosystems, Vancouver, BC, Canada) or the Hamilton MicroLab Star (Hamilton, Reno, 
NV, USA) according to the flow rate outlined in the text. LNPs were then dialyzed in PBS 
at 4ºC overnight. Dynamic light scattering was used to determine LNP size and 
polydispersity index. In brief, 10 μL of dialyzed LNPs were diluted in 700 μL PBS and 
analyzed at a fixed temperature of 25ºC. Encapsulation efficiency was calculated by 
incubating LNPs with nucleic acid green dye to measure the amount of free pDNA that 
was not encapsulated. LNPs were then incubated with Triton X to break open the LNPs 
and nucleic acid green dye was added to stain the encapsulated pDNA. Absorbance was 
read using a plate reader at 480 nm excitation. Percent encapsulation was then calculated 




Murine B16-F10 cells were cultured at 5% CO2 and maintained in DMEM:F12 medium 
(Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum and 
1% Penicillin-Streptomycin (Thermo Fisher Scientific, Waltham, MA, USA). LNP 
transfection was performed when cells reached 90% confluence. LNPs were diluted in 
media to reach a concentration of 1 μg/mL, 3 μg/mL, and 6 μg/mL and were added directly 
to cells. Lipofectamine 3000 was used by following the manufacturer’s protocol (Thermo 
Fisher Scientific, Waltham, MA, USA). Real-time cell imaging was done using the 
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IncuCyte ZOOM (Essen BioScience, Inc., Ann Arbor, MI, USA). Fluorescence and 
confluence were measured and analyzed using the IncuCyte ZOOM Analysis software. 
 
LNP In Vivo Studies 
Male albino mice (AstraZeneca Granta Park, Cambridge, UK) were administered 100 μL 
N2-LNP or H2-LNP loaded with mRNA luciferase (CleanCap Fluc mRNA, L-7602, TriLink 
Biotechnologies, San Diego, CA, USA) or pDNA luciferase at a dose of 0.25 mg/kg. 
Control mice were administered 100 μL PBS. Mice were injected with 150 mg/kg of D-
luciferin by intraperitoneal injection prior to imaging at 6, 24, and 48 hours post LNP 
injection, anesthetized with 2-4% inhaled isoflurane in O2, and imaged using the IVIS 
Spectrum In Vivo Imaging System (PerkinElmer, Waltham, MA, USA). All animal studies 
were approved by and conducted in compliance with the polices of AstraZeneca UK.   
 
AAV Production 
The AAV expression plasmid containing mCherry (#87916, Addgene, Watertown, MA, 
USA) was transformed into competent DH5α E. coli (Thermo Fisher Scientific, Waltham, 
MA, USA). Plasmids were isolated using the Qiagen Plasmid Maxi Kit (Qiagen, Hilden 
Germany). Isolated mCherry pDNA was then used to generate AAV8 by the University of 
Michigan Vector Core.  
 
AAV In Vivo Studies 
Male C57BL/6J mice (#000664, Jackson Labs, Bar Harbor, ME, USA) were injected with 
AAV8 as previously described (8,49). For intravenous injection, 100 μL 1012 vg/mL AAV8-
mCherry was administered via the tail vein. For intra-BAT and intra-WAT injection, mice 
were anesthetized with 2-4% inhaled isoflurane in O2 and a small area in the interscapular 
region or posterior subcutaneous region was shaved to access BAT of psWAT. A 1-2 cm 
incision was made, and the skin was peeled back to visualize the interscapular BAT or 
psWAT. For each, 100 μL 1012 vg/mL AAV8-mCherry was administered to each tissue by 
inserting the needle into the depot at 2-3 distinct sport and dispensing the virus. Freshly 
dissected tissues were placed in PBS and stored on ice followed by imaging using a Nikon 




Total RNA was purified from frozen tissue using RNA STAT-60 (Tel Test, Alvin, TX, 
USA) according to the manufacturer’s instructions. One μg of total RNA was reverse-
transcribed to cDNA using M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, CA, 
USA). qPCR was performed using a StepOnePlus System (Applied Biosystems, 
Beverly Hills, MI, USA). mCherry qPCR primers (mCherry qPCR F: 
GAGGCTGAAGCTGAAGGAC, mCherry qPCR R: GATGGTGTAGTCCTCGTTGTG) 
were validated with a cDNA titration curve and product specificity was evaluated by 
melting curve analysis and gel electrophoresis of the qPCR products. Gene expression 
was calculated using a cDNA titration curve within each plate and then normalized to 
the expression of peptidylprolyl isomerase A (Ppia) mRNA (Ppia qPCR F: 




   
 
Table 2.1. Physical properties of LNPs. A library of LNPs was generated using two 
microfluidics devices: the NanoAssemblr Benchtop and the Hamilton MicroLab Star. By 
altering the lipid molarity, PEG molarity, N/P ratio, and mixing rate, we were able to 
formulate LNPs with different sizes and physical characteristics. * indicates the lead 






Figure 2.1. Microfluidic mixing formulates LNPs with different physical properties. 
(a) LNPs were formulated by the rapid mixing of aqueous and lipid phases to create a 
monodisperse suspension of LNPs encapsulating pDNA. (b-c) LNPs diameter and 
polydispersity index were determined using dynamic light scattering. In total, four 
formulations were generated using the NanoAssemblr Benchtop (N1, N2, N3, N4) and 
Hamilton MicroLab Star (H1, H2, H3, H4). Error bars represent standard deviation of 
diameter and polydispersity index as measured from three technical replicates. Figure is 








Figure 2.2. LNPs transfect cells in vitro and are non-cytotoxic. (a) LNP cellular 
transfection proceeds by endosomal-mediated uptake, destabilization of the endosomal 
membrane, and release of pDNA. (b) Percent encapsulated pDNA in N2-LNPs and H2-
LNPs. (c) Percent mCherry+ B16-F10 cells over 84 hours. (d) mCherry count (red 
calibrated unit [RCU]) after 84 hours for N2-LNPs and H2-LNPs at increasing doses. (e) 
Percent confluence of B16-F10 cells after 84 hours of treatment with LNPs or 
Lipofectamine 3000; data is normalized to the control. Error bars represent standard 






Figure 2.3. Systemic delivery of mRNA-LNPs primarily transfects liver but not 
adipose tissues. (a) Representative IVIS images of mice 6 hours post injection with PBS, 
N2-LNPs, or H2-LNPs (0.25 mg/kg) loaded with luciferase mRNA (n = 3). Average 
radiance taken at 6 hours post injection. Diameter of LNPs as measured by dynamic light 
scattering. (b) Average radiance in BAT, psWAT, eWAT, liver, spleen, kidney, lung, and 
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Figure 2.4. pDNA-LNPs localize to adipose tissues and reticuloendothelial organs 
following systemic delivery. (a) IVIS images of mice 48 hours post injection with LNPs 
(0.25 mg/kg) loaded with luciferase pDNA (n = 3). Average radiance at 48 hours post 
injection. LNP diameter was determined by dynamic light scattering. (b) Average radiance 
of various tissues taken at 48 hours after injection. All data are from male mice. Error bars 









Figure 2.5. Route of administration strongly influences AAV8 transduction 
efficiency of adipose tissues. (a) Mice administered 100 μL 1012 vg/mL AAV8-mCherry 
by intravenous injection via the tail vein (n = 3). Relative mCherry mRNA expression; 
mRNA normalized to Ppia. (b) Mice 100 μL 1012 vg/mL AAV8-mCherry by intra-BAT 
injection (n = 3). Relative mCherry mRNA expression; mRNA normalized to Ppia. (c) Mice 
100 μL 1012 vg/mL AAV8-mCherry by intra-WAT injection (n = 3). Relative mCherry 
mRNA expression; mRNA normalized to Ppia. (d) Confocal microscopy of freshly 
dissected BAT, psWAT, eWAT, and liver from mice 14 days post injection; 200x 
magnification, scale bar, 100 μm (n = 3). Data shown are from male mice. Error bars 
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BAd-CRISPR: Inducible Gene Knockout in Brown Adipose Tissue of Adult Mice 
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ABSTRACT 
CRISPR/Cas9 has enabled inducible gene knockout in numerous tissues, however, its 
use has not been reported in brown adipose tissue (BAT). Therefore, we developed the 
brown adipocyte CRISPR (BAd-CRISPR) methodology in which an adeno-associated 
virus (AAV8) is used to administer a single guide RNA (sgRNA) directly to BAT of mice 
expressing Cas9 in brown adipocytes to enable rapid interrogation of one or multiple 
genes and streamline the paths to discovery compared to traditional transgenic 
approaches. We show that local administration of AAV8-sgRNA to the interscapular BAT 
of adult mice robustly transduces brown adipocytes and ablates expression of adiponectin 
(ADIPOQ), adipose triglyceride lipase (ATGL), fatty acid synthase (FASN), perilipin 1 
(PLIN1), and stearoyl-CoA desaturase 1 (SCD1) by >90%. BAd-CRISPR induced 
frameshift mutations and suppressed target gene mRNA expression but did not lead to 
substantial accumulation of off-target mutations in BAT. We used BAd-CRISPR to create 
an inducible uncoupling protein 1 (UCP1) knockout mouse to assess effects of UCP1 loss 
on adaptive thermogenesis in adult mice. Interestingly, inducible UCP1 knockout did not 
impair adaptive thermogenesis when adult mice were housed at 5ºC. BAd-CRISPR Ucp1 
mice had elevated circulating concentrations of fibroblast growth factor 21 (FGF21) and 
changes in BAT gene expression consistent with an increase in heat-producing 
peroxisomal lipid oxidation at the expense of mitochondrial metabolism, and energy 
wasting via an increase in both protein synthesis and turnover. Thus, we show that BAd-




Adipose tissues play important physiological roles in the maintenance of whole-body 
energy homeostasis and metabolism. Beyond simply storing excess energy in the form 
of triacylglycerols, adipose tissues are found throughout the body in distinct depots, each 
with unique functions. Classically, adipose tissues are classified as white (WAT), which 
are found in subcutaneous and visceral depots, or brown (BAT), which are found in the 
interscapular, periaortic, perirenal, and intercostal depots (1,2). Beige/BRITE adipocytes, 
a distinct adipocyte population induced with cold exposure and adrenergic agonists, are 
found within some WAT depots (3). Adipose tissue is also located in more specialized 
areas such as the bone marrow, intramuscular, periarticular, pericardial, epicardial, retro-
orbital, and dermal depots (1,4,5). Collectively, these tissues comprise the largest 
endocrine organ in the body and regulate satiety, carbohydrate and lipid metabolism, 
bone homeostasis, blood pressure, and the immune response (6,7). Thus, understanding 
these dynamic adipose tissues is integral to our understanding of their roles in metabolic 
disorders such as obesity or lipodystrophy (8).  
Our understanding of adipose tissues has fundamentally relied upon the use of 
transgenic mouse models. Conditional models using the Cre/LoxP system have enabled 
tissue-specific knockout to study a gene of interest. Several Cre-recombinase lines have 
been developed in which Cre expression is driven by promoters/enhancers for Adipoq, 
Fabp4, PdgfRα, Prx1, or Ucp1 (9-11). Additionally, inducible transgenic models including 
Adipoq-CreERT, Ucp1-CreERT, and “AdipoChaser” have afforded control over the timing of 
gene knockout (9,10,12,13). Whilst these transgenic mouse models have undoubtedly 
led to advances in adipose tissue research, they are not without limitations. For example, 
Adipoq-Cre causes recombination in some osteoblasts, whereas Fabp4-Cre causes 
widespread recombination due to expression early in development (9,11,14,15). 
Moreover, tamoxifen administration to CreERT mice has been shown to decrease adipose 
mass, particularly when combined with gene knockout (16). Cre expression can also 
change generation-to-generation in mouse colonies (14). Another critical limitation is that 
Cre mice must be bred to mice harboring a floxed allele, which in certain circumstances, 
necessitates the generation of a new mouse strain. Generating a novel transgenic strain 
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can require labs to commit years and significant investment to developing and breeding 
before performing any experiments (17). Therefore, more efficient strategies are required 
to improve how adipose tissues are studied in vivo.  
An efficient strategy to modulate gene expression in vivo has centered upon the 
use of CRISPR/Cas9 delivery for inducible knockout in somatic tissues. CRISPR/Cas9 is 
comprised of the Cas9 endonuclease, which creates double-strand DNA breaks, and a 
single guide RNA (sgRNA), which is a programmable RNA molecule that directs Cas9 to 
its target site for mutagenesis (18). Both the Cas9 endonuclease and a sgRNA can 
therefore be genetically encoded and packaged into a virus for somatic knockout in adult 
tissues (17). Viral delivery of the CRISPR/Cas9 machinery for inducible knockout offers 
several advantages over conventional germline knockouts as the timing, tissue, and 
target can be closely controlled (17). Moreover, embryonically lethal genes can be studied 
in this context. Several iterations of viral CRISPR/Cas9 delivery have been developed 
(19). For example, both Cas9 and sgRNA have been packaged into viral vectors and 
administered to the lung epithelium, liver, and hippocampus (20-22). Additionally, 
transgenic approaches have created inducible- and tissue-specific Cas9-expressing 
mouse models to which sgRNAs are delivered using adeno-associated viruses (AAVs) 
(19). Platt et al. developed the Cre-dependent Cas9 knockin mouse which when bred to 
a tissue-specific promoter-driven Cre, enables somatic genome editing in adult tissues 
(23). As proof of concept, AAVs encoding a sgRNA to Kras, p53, or Lkb1 were delivered 
to the lung to accurately model adenocarcinoma disease progression. This Cas9 model 
has been further adapted for inducible somatic gene knockout in heart, skin, intestine, 
and thymus, thereby demonstrating its broad versatility across different tissues (24,25). 
Whereas AAV-mediated CRISPR/Cas9 gene transfer has proven useful for 
modeling disease in numerous tissues, its use in adipose tissues has not been reported. 
This is largely due to the fact that adipose tissues are located throughout the body in 
distinct locations, making transduction difficult (26-28). Moreover, mature adipocytes only 
comprise 11-40% of the total cell population of adipose tissues and lack unique cell 
surface receptors, which makes it challenging for a vector to navigate specifically to the 
adipocytes (26-28). Currently, CRISPR/Cas9 has only been accomplished in 
preadipocyte culture models. For example, Shen and colleagues transduced primary 
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preadipocytes using a nonviral vector to administer CRISPR/Cas9 and disrupt expression 
of the Nrip1 gene (29). In another study, Kamble et al. electroporated CRISPR/Cas9 into 
human preadipocytes and demonstrated efficient knockout of Pparg and Fkbp5 (30). Yet 
while these studies show that CRISPR/Cas9 can function in preadipocyte models, the 
field has yet to unlock the full potential of CRISPR/Cas9 for somatic gene editing in vivo. 
Thus, we developed a method for CRISPR/Cas9 inducible gene knockout in adipose 
tissues. We optimized this method for knocking out genes in BAT, as it is found 
predominantly in the interscapular depot in rodents and is easily accessible. BAT is the 
main site of adaptive thermogenesis and uncouples oxidative phosphorylation to generate 
heat in response to cold stress (31). BAT also has important endocrine functions, 
secreting molecules required for the thermogenic response that stimulate hypertrophy, 
vascularization, innervation, and blood flow to BAT (32). In humans, active BAT is 
inversely associated with body mass index, making it a potentially attractive candidate for 
combatting obesity (33).  
Herein we report that CRISPR/Cas9 can induce gene knockout in BAT. Our 
methodology, termed brown adipocyte CRISPR (BAd-CRISPR), integrates viral delivery 
with the established Cre/LoxP approach to significantly decrease the time and investment 
required to knockout genes in BAT of adult mice. We accomplished this by administering 
AAV8-sgRNA to brown adipocyte-specific Cas9 expressing mice. BAd-CRISPR efficiently 
targeted Adipoq, Atgl, Fasn, Plin1, Scd1, and Ucp1 in BAT, decreasing expression by 80-
99%. We also showed that BAd-CRISPR inducible gene knockout recapitulates 
previously reported phenotypes for ATGL and PLIN1 knockout mice. Importantly, we 
show that BAd-CRISPR streamlines the path to generation of transgenic mice and affords 
the ability to target multiple genes in BAT simultaneously. Lastly, we used BAd-CRISPR 
to create inducible UCP1 knockout mice and found that loss of UCP1 expression in adult 
mice did not impair adaptive thermogenesis when mice were cold stressed at 5ºC. 
Interestingly, we observed an increase in Fgf21 expression in BAT as well as dramatic 
changes to the transcriptome predicted to increase heat production through peroxisomal 
lipid oxidation and futile cycling through elevated protein synthesis and degradation. 
Thus, BAd-CRISPR serves as a more efficient alternative approach to generate BAT-




Transfection of adipocyte precursors with sgRNAs predominantly causes 
frameshift mutations in the target gene 
To induce gene knockout in adult mice, we devised the BAd-CRISPR method, in which 
AAV-sgRNAs are administered to mice expressing Cas9. We created a cloning strategy 
that facilitates incorporation of a U6 promoter-driven sgRNA into an AAV expression 
vector (Supplement 3.1a). The AAV expression vector also contains a CMV-driven 
mCherry fluorescent marker and 5’ and 3’ inverted terminal repeats (Figure 3.1a). We 
designed sgRNAs using the CRISPOR design tool and selected sgRNAs that targeted 
early coding regions, lacked 0- or 1-base mismatch off-target sites, and had high Cutting 
Frequency Determination (CFD) scores (34). The CFD score, developed by Doench and 
Fusi, calculates the off-target potential of a sgRNA by considering the position and 
identities of mismatched nucleotides in the sgRNA sequence (35). As a general rule, 
sgRNAs should have a CFD score ≥0.2 (35). All of the sgRNAs designed had a CFD 
score >0.4 (Supplement 3.1b).  
To test each sgRNA, AAV expression vectors were transfected into primary 
adipocyte progenitor cells isolated from Rosa26-Cas9 knockin mice (23). Transfected 
cells were sorted for mCherry expression using flow cytometry and DNA was analyzed 
by Sanger sequencing. Primers flanking sgRNA cut sites were used to sequence Adipoq, 
Atgl, and Plin1, and traces were analyzed using the Tracking of Indels by Decomposition 
(TIDE) and Synthego ICE Analysis tools (36). Corresponding sgRNA efficiencies were 
observed in both the forward (data not shown) and reverse sequence traces (Figure 3.1b-
d). Synthego ICE analysis identified 1-base deletions as the predominant indel 
contribution across all sgRNAs tested. To calculate the total mutations resulting in a 
frameshift, we divided the number of frameshift mutations by the total number of predicted 
mutations. Frameshift mutations accounted for 97.5%, 92.5%, and 95.5% of the total 
mutations for sgRNAs targeting Adipoq, Atgl, and Plin1, respectively (Figure 3.1b-d). 
Analyzing CRISPR/Cas9-induced mutations using decomposition of Sanger sequence 
traces is an easy to use and cost-effective method for assessing a small number of 
samples (37). TIDE and next generation sequencing analyses have been shown to be 
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highly correlated; however, frequencies calculated using TIDE often underrepresent the 
true editing efficiency when compared to next generation sequencing (38). Thus, the true 
editing efficiency for each sgRNA is likely higher. After validating sgRNA efficiencies in 
vitro, AAV expression vectors were used to generate AAVs encoding the sgRNA and 
mCherry fluorescent marker. For transducing adipose tissues, AAV serotype 8 (AAV8) 
has been used most extensively owing to its favorable tropism for brown and white 
adipocytes (26-28,39-44). 
 
BAd-CRISPR mice express Cas9 exclusively in BAT 
Although AAV8 is the gold standard for transducing adipose tissues, its relatively small 
genome size (~4.7 kb) limits packaging S. pyogenes Cas9 with the sgRNA and mCherry 
transgene (26-28). Therefore, we developed a mouse line that expresses Cas9 
specifically in brown adipocytes (BAd-CRISPR) by breeding two existing mouse lines: 
Ucp1 promoter-Cre recombinase (B6.FVB-Tg(Ucp1-cre)1Evdr/J) and Cre-dependent 
Cas9-GFP (Rosa26-LSL-Cas9) (Supplement 3.2a) (10,23). As expected, Cas9 is 
detected by immunoblot analyses in lysates from BAT of BAd-CRISPR mice but not from 
posterior subcutaneous WAT (psWAT), parametrial WAT (pmWAT), or liver, nor is it 
found in any tissues in mice lacking Ucp1-Cre expression (Supplement 3.2b). Confocal 
microscopy of freshly dissected tissues showed Cas9-GFP expression exclusively in BAT 
but not in psWAT, pmWAT, nor liver (Supplement 3.2c). Thus, these mice are a suitable 
model to assess the effectiveness of CRISPR/Cas9 for inducible gene knockout in brown 
adipocytes. 
 
Local injection of AAV8-mCherry to the interscapular BAT robustly transduces BAT 
with minimal leak to other tissues 
Next, we optimized a delivery strategy using AAV8 to administer sgRNAs for BAd-
CRISPR inducible gene knockout. Initially, we attempted tail vein injection as well as 
intraperitoneal injection of 100 μL 1012 vg/mL AAV8-mCherry to transduce all adipose 
tissues, both of which were unsuccessful and led to substantial transduction of liver (data 
not shown). By contrast, direct injection of AAV8 into an adipose tissue has been shown 
to significantly improve transduction efficiency and reduce vector accumulation in liver, 
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heart, and lung (26-28,39). To test this, we directly injected 100 μL 1012 vg/mL AAV8-
mCherry into interscapular BAT or psWAT and sacrificed mice after 14 days in 
accordance with previously established protocols (39,45). Although direct injection into 
psWAT transduced only a minority of white adipocytes (data not shown), direct injection 
to interscapular BAT showed widespread and robust mCherry expression throughout BAT 
(Supplement 3.3a-b). With direct injection to BAT, a small number of cells in liver were 
also mCherry positive but mCherry signal was not observed in WAT depots examined 
(Supplement 3.3a-b). Using quantitative PCR (qPCR), we found that mCherry mRNA 
expression was enriched in the interscapular BAT following local injection, with small or 
undetectable expression in psWAT, pmWAT, liver, spleen, heart, lung, or kidney 
(Supplement 3.3b). 
 
BAd-CRISPR induces knockout of Adipoq, ATGL, FASN, PLIN1, and SCD1 in brown 
adipocytes of adult mice 
After validating robust BAT transduction using AAV8 direct injection, we next sought to 
apply the BAd-CRISPR method for inducible gene knockout. We targeted genes highly 
expressed in brown adipocytes and administered 100 μL 1012 vg/mL AAV8-sgRNAs 
targeting Adipoq, Atgl, Fasn, Plin1, Scd1, or a Control sgRNA, directly into the 
interscapular BAT of BAd-CRISPR mice (n = 3 or 4 mice). BAd-CRISPR mice were 
sacrificed 14 days post-injection and BAT was homogenized to isolate mRNA and protein. 
Impressively, mRNA and protein expression for each target were reduced by 80-99% 
(Figure 3.2a-e). It should be noted, that despite performing a thorough transcardial 
perfusion, we detected albumin in BAT homogenate (data not shown), suggesting that 
blood was not completely cleared from the tissue. Thus, cellular ADIPOQ protein levels 
are likely reduced more than what is observed in the immunoblot (Figure 3.2a). To further 
assess AAV8 transduction efficiency in BAT, we performed immunofluorescence for 
ATGL expression in BAd-CRISPR Atgl mice (Figure 3.2f). ATGL was only detected in a 
few brown adipocytes (white arrows), indicating that direct injection of AAV8 transduces 




BAd-CRISPR Atgl, BAd-CRISPR Plin1, and BAd-CRISPR Fasn inducible knockouts 
recapitulate previously described BAT phenotypes 
To investigate whether BAd-CRISPR can be used to recapitulate known knockout 
phenotypes in BAT, we further characterized BAd-CRISPR Atgl, BAd-CRISPR Plin1, and 
BAd-CRISPR Fasn inducible knockouts described in Figure 3.2 and compared our 
results to phenotypes identified using traditional transgenic approaches (46-50). BAd-
CRISPR Atgl inducible knockout caused significant BAT hypertrophy compared to BAd-
CRISPR Control mice and histological sectioning revealed a striking whitening of BAT 
(Figure 3.3a-b). These results mirror the observed phenotypes reported using the global 
and BAT-specific inducible ATGL knockout mice, which also have marked hypertrophy 
and whitening (46,47). By contrast, BAd-CRISPR Plin1 inducible knockout led to a 
decrease in BAT weight coupled with the loss of multilocular brown adipocyte morphology 
and the emergence of distinct, but rare unilocular lipid droplets dispersed throughout BAT 
(Figure 3.3a-b). These data bear similarity to the global PLIN1 knockout mouse models, 
which had smaller or complete loss of lipid droplets in BAT (48,49). Interestingly, BAT 
weight was not altered in the two reported PLIN1 knockout models (48,49). This 
difference may be explained by the fact that in the BAd-CRISPR inducible knockout 
model, mice lose PLIN1 expression as adults compared to the global knockout mice that 
lack PLIN1 from birth. Second, both reported PLIN1 knockout models are whole-body 
deletion, whereas BAd-CRISPR Plin1 inducible knockout is brown adipocyte specific. 
Lastly, BAd-CRISPR Fasn mice showed a decrease in total lipid droplet size and BAT 
tissue weight relative to BAd-CRISPR Control mice (Figure 3.3a-b). These data replicate 
the phenotype observed in the brown adipocyte Ucp1-Cre FASNflox/flox mice, which had a 
reduction in lipid droplet size (50). Thus, our method can be used to inducibly knockout 
genes of interest in brown adipocytes of adult mice, and we have validated its effects on 
several genes by phenocopying previous loss of function models.  
 
BAd-CRISPR enables simultaneous knockout of ATGL and PLIN1 in brown 
adipocytes 
To test whether BAd-CRISPR can be used to knockout multiple genes in BAT 
concurrently, we targeted Atgl and Plin1 using two separate AAV8 vectors. We chose Atgl 
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and Plin1 as targets because they have opposing functions; ATGL hydrolyzes 
triacylglycerols whereas PLIN1 protects against this hydrolysis (51,52). Moreover, it has 
been established that ATGL knockout in BAT causes hypertrophy and whitening whereas 
PLIN1 knockout in BAT decreases tissue size and causes a darker morphology, therefore 
we would have a visual phenotype with which to evaluate the feasibility of a double 
knockout (Figure 3.3a-b) (46-49). BAd-CRISPR mice and Rosa26-LSL-Cas9 mice 
lacking functional Cas9 (BAd-CRISPR Control) were administered 100 μL 1010 vg/mL 
AAV8-sgRNA targeting Atgl alone, Plin1 alone, or Atgl and Plin1 in combination. BAd-
CRISPR Atgl mice had profound whitening and BAT hypertrophy whereas BAd-CRISPR 
Plin1 mice had a darker BAT morphology and decreased tissue size (Figure 3.4a-c). By 
contrast, BAd-CRISPR Atgl + Plin1 mice displayed a “hybrid” morphology characterized 
by a mild increase in BAT weight compared to BAd-CRISPR Control mice, which were 
also administered both sgRNAs but lacked Cas9 expression (Figure 3.4a-c). Collectively, 
these data demonstrate that BAd-CRISPR is scalable for inducible knockout of multiple 
genes in brown adipocytes. 
 
BAd-CRISPR ablates UCP1 expression in brown adipose tissue 
The Ucp1 knockout mouse has been extensively studied since the mice were first 
generated by Enerbäck and colleagues in 1997 (53). Thus, it is well known that UCP1-
deficient mice (Ucp1-/-) rely on compensatory mechanisms such as increased shivering, 
activation of futile cycles, or recruitment of beige/BRITE adipocytes to maintain body 
temperature when cold stressed (54). These adaptations allow Ucp1-/- mice to tolerate a 
stepwise reduction in ambient temperature from thermoneutrality (~30ºC) to extreme cold 
(-10ºC), however, immediate cold exposure at 4ºC can prove lethal for mice lacking 
functional UCP1 (54-57). After canvassing the literature, we were intrigued to find that 
whilst a plethora of papers have reported on the consequences of constitutive global 
UCP1 knockout, no studies have reported the effect of inducible UCP1 knockout on 
adaptive thermogenesis in adult mice. Thus, we sought to characterize inducible UCP1 
knockout using BAd-CRISPR. 
To show that BAd-CRISPR could be used to inducibly knockout UCP1 in adult 
mice, we administered 100 μL 1012 vg/mL AAV8-UCP1 sgRNA directly into interscapular 
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BAT. Mice were sacrificed at 0 (no virus), 2, 7, or 14 days post-injection to assess degree 
of knockout (n = 3 mice per timepoint). As expected, confocal microscopy of freshly 
dissected tissue at 14 days revealed robust mCherry expression in BAT, with no mCherry 
detected in psWAT or pmWAT, and a low signal detected in liver compared to BAT 
(Figure 3.5a). Importantly, Cas9-GFP expression was exclusive to BAT and was not 
detected in any other tissues examined (Figure 3.5a). We also observed an increase in 
mCherry mRNA expression between 0 and 14 days (Figure 3.5b). To assess for 
mutations in BAd-CRISPR Ucp1 mice, we performed a genomic cleavage assay on cDNA 
since Ucp1 mRNA is expressed specifically in brown adipocytes (Figure 3.5c). We 
observed aberrant PCR product bands at 7 and 14 days post injection but only the WT 
band at 0 and 2 days (Figure 3.5c). Interestingly, we observed multiple PCR products 
with or without addition of T7 endonuclease at 7 and 14 days, suggesting amplification of 
mutations causing substantial deletions at the target site. To further confirm mutations, 
we performed Sanger sequencing on cDNA at the Ucp1 sgRNA cut site and observed 
aberrant traces in mice at 14 days (Figure 3.5d). Impressively, Ucp1 mRNA expression 
was decreased by ~90% 2-days post injection and by ~99% at 7 and 14 days (Figure 
3.5e). These results were further confirmed by immunoblot analyses, which showed a 
dramatic reduction in UCP1 protein expression at 7 days and near total loss by 14 days 
without loss of ADIPOQ expression (Figure 3.5f). Increased lipid accumulation, observed 
as a whitening of BAT on histological evaluation, has been reported previously for Ucp1-
/- mice, and we also observe a slight whitening in histological sections of BAT at 2, 7, and 
14 days post-injection, relative to mice that were not administered AAV8-UCP1 sgRNA 
(day 0) (Supplement 3.4a) (53). UCP1 protein turnover in the basal state occurs by ~4 
days and parallels the proteolytic rates of other mitochondrial proteins (58,59).  
To show that BAd-CRISPR Ucp1 inducible knockout occurs as a result of 
CRISPR/Cas9 mutagenesis, we administered AAV8-UCP1 sgRNA to Rosa26-LSL-Cas9 
mice that were bred to Ucp1-Cre mice (Ucp1-Cre+) or not (Ucp1-Cre–). UCP1 knockout 
occurred only when Rosa26-LSL-Cas9 mice were bred to the Ucp1-Cre background and 
therefore had functional Cas9 expression (Supplement 3.4b-c). We also showed that 
UCP1 knockout only occurs when BAd-CRISPR mice are administered AAV8-UCP1 
sgRNA and not when administered AAV8-Control sgRNA (Supplement 3.4d-e). To 
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quantify transduction efficiency, we performed immunofluorescent analyses on fixed BAT 
from BAd-CRISPR Ucp1 or BAd-CRISPR Control mice. BAd-CRISPR Ucp1 caused a 
near total loss of UCP1 expression in brown adipocytes, suggesting that viral transduction 
is nearly 100% (Supplement 3.4f). We did observe very few UCP1 positive cells 
dispersed throughout BAT (Supplement 3.4f). It should be noted that the anti-UCP1 
antibody cross-reacted with endomucin positive cells of the vasculature, however, there 
is a clear difference in UCP1 expression between BAd-CRISPR Control and BAd-
CRISPR Ucp1 mice (Supplement 3.4f). Collectively, these data provide strong evidence 
that CRISPR/Cas9 induces knockout of Ucp1 in brown adipocytes of adult mice in vivo. 
 
BAd-CRISPR Ucp1 inducible knockout mice defend core body temperature and 
have elevated FGF21 
Next, we used BAd-CRISPR Ucp1 mice to determine if adult mice could maintain body 
temperature when cold stressed at 5ºC following inducible UCP1 knockout in BAT. 
Female 8-10 week old mice were implanted with an intraperitoneal telemeter to monitor 
core body temperature one-week prior to AAV8 administration. All mice were single 
housed at room temperature (20-21ºC) and nest building materials were withheld 
throughout the study. We administered 100 μL 1012 vg/mL AAV8-UCP1 sgRNA or AAV8-
Control sgRNA to the interscapular BAT (n = 4 or 5 mice) and mice were allowed to 
recover for 14 days (Figure 3.6a). Mice were then cold stressed at 5ºC for 24 hours. BAd-
CRISPR induced complete loss of UCP1 expression at both the mRNA and protein levels 
(Figure 3.6b-c). Despite an apparent total knockout of UCP1 in BAT, there was no 
difference in body temperature when mice were housed at room temperature (20-21ºC) 
or cold stressed (5ºC) (Figure 3.6d-e, Supplement 3.5a). The same is true for the 
aforementioned Ucp1-/- mice, which, when pre-acclimated to mild cold stress, are cold 
tolerant (57). We did not observe changes to body weight, BAT weight, or average daily 
food intake between BAd-CRISPR Control and BAd-CRISPR Ucp1 mice (Supplement 
3.5b-d). Moreover, UCP1 protein expression was undetected in inguinal WAT in these 
mice, suggesting that thermogenic mechanisms besides beige/BRITE adipogenesis are 
operative in BAd-CRISPR Ucp1 mice (Supplement 3.5e). Interestingly, we did observe 
a significant increase in Fgf21 expression in BAT (Figure 3.6f). It has been reported that 
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circulating FGF21 is increased in response to cold stress as a compensatory mechanism 
for adaptive thermogenesis (32,60,61). Thus, we repeated this experiment using BAd-
CRISPR Ucp1 inducible knockout mice, Ucp1-/- mice, and Rosa26-LSL-Cas9 (BAd-
CRISPR Control) mice. Interestingly, we observed an “intermediate” increase in serum 
FGF21 levels in BAd-CRISPR Ucp1 inducible knockout mice compared to Ucp1-/- and 
BAd-CRISPR Control mice after being cold stressed at 5ºC for 24 hours (Figure 3.6g). 
These data further support the role of FGF21 in adaptive thermogenesis (32,60,61). 
 
Gene profiling of BAT from BAd-CRISPR Ucp1 mice suggests peroxisomal lipid 
oxidation and increased protein synthesis/turnover as a compensatory 
thermogenic process 
Thermoneutrality in mice is approximately 30ºC whereas mice are typically housed 
between 20-22ºC and are therefore under a chronic mild cold stress (62,63). To explore 
potential mechanisms by which BAd-CRISPR Ucp1 mice adapt to a mild cold stress in 
the absence of UCP1, we performed RNA sequencing (RNAseq) on BAT from mice 
administered 100 μL 1012 vg/mL AAV8-UCP1 sgRNA or AAV8-Control sgRNA. Of the 
>20,000 genes identified from RNAseq, 1,056 were found to be differentially expressed. 
As expected, the most statistically significant difference was the ~90% suppression of 
Ucp1 mRNA in BAT of BAd-CRISPR Ucp1 mice (Figure 3.7a). We then used gene set 
enrichment analysis (GSEA) to identify significantly up- and down-regulated pathways in 
response to inducible UCP1 knockout. GSEA indicated up-regulation of pathways 
involved in fatty acid metabolism, the peroxisome, unfolded protein response, protein 
secretion, and mTORC signaling (Figure 3.7b). Pathways related to the mitochondrial 
electron transport chain and heat production by uncoupling proteins were down-
regulated, as was the citric acid cycle (Figure 3.7b). Next, we mined GSEA pathways for 
genes that were significantly up- or down-regulated. We clustered genes based on 
pathways to generate a heat map and found that BAd-CRISPR Ucp1 inducible knockout 
mice have elevation of peroxisome and lipid metabolism genes, which strongly suggests 
reliance on peroxisomal β-oxidation of fatty acids to generate heat (Figure 3.7c) (64). We 
also observed a down-regulation of mitochondrial genes, particularly those involved in the 
electron transport chain and coupled respiration (mt-Nd1, mt-Nd3, mt-Nd4, mt-Nd6, mt-
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Co1, and mt-Atp6) (Figure 3.7c). Interestingly, we observed elevated expression of tRNA 
synthetase genes– Cars, Nars, Yars, Wars, Tars, Sars, Gars, Iars, and Eprs– which is 
predicted to increase the rate of translation (65,66). We also see up-regulation of many 
genes coding for subunits of the proteasome, suggesting a futile cycle involving both 
increased synthesis and turnover of proteins (Figure 3.7c). These data may also indicate 
dynamic de novo synthesis of proteins required for adaptive thermogenesis as well as for 
protection against cellular stress in BAd-CRISPR Ucp1 mice (67,68). Lastly, we 
compared differentially expressed genes in BAd-CRISPR Ucp1 mice to Ucp1-/- mice on 
a normal chow diet at 20ºC (Figure 3.7d) (69). In total, 256 genes were found to overlap. 
Interestingly, these overlapping genes cluster to pathways involved in the peroxisome, 
lipid metabolism, and the proteasome, further supporting a compensatory mechanism for 
maintaining adaptive thermogenesis.  
 
CRISPR/Cas9 does not lead to observable off-target mutations in BAT of BAd-
CRISPR Ucp1 mice 
CRISPR/Cas9 mutagenesis has been shown to have off-target effects at loci that bear 
similarity to the sgRNA sequence (70). These off-target mutations can impact genome 
integrity and cause unwanted phenotypic changes that obscure results. Using CRISPOR 
and the Synthego CRISPR Design tool, we identified 7 off-target loci for the Ucp1 sgRNA 
(Figure 3.8a). Off-target loci had 3 or 4-base mismatches; no off-targets contained fewer 
than 3 base mismatches. We focused on the highest predicted off-target identified by both 
tools–which occurred in an intergenic space on chromosome 18– in addition to off-target 
sites that were found within exons or introns of genes (Figure 3.8a). To check for 
mutations at off-target sites, we performed unbiased whole genome sequencing on BAT 
from two BAd-CRISPR Ucp1 mice. Whole genome sequencing data was analyzed using 
the Integrative Genome Viewer (IGV) and CRISPResso2 (71,72). We observed mutations 
in 36.1% of reads on average at the Ucp1 locus compared to 1.8% at the intergenic space 
and 0.0% at all other sites, respectively (Figure 3.8a). To probe the intergenic off-target 
in more detail, we analyzed whole genome sequencing data from both BAd-CRISPR 
Ucp1 mice using CRISPResso2 and found a single substitution at position 1 of the sgRNA 
sequence in 1 out of 51 total reads at this locus (Figure 3.8b). CRISPResso2 did not 
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identify any insertions or deletions in reads at this off-target site. Next, we performed a 
genomic cleavage assay on genomic DNA from BAd-CRISPR Ucp1 mice sacrificed at 
different timepoints and did not observe aberrant mutant PCR or T7 cleavage products at 
the intergenic off-target site (Figure 3.8c). Therefore, mutations at this off-target site are 
likely very rare or are background mutations in this mouse line that are different from the 
reference. Additionally, we probed RNAseq data from BAd-CRISPR Ucp1 mice to 
determine if gene expression at the coding regions was disrupted. We did not observe 
any indication that gene expression was altered at off-target loci (Figure 3.8d). Although 
one off-target site located within an intron of Rftn1 had decreased mRNA expression in 
the BAd-CRISPR Ucp1 mice, this locus has three mismatches proximal to the PAM and 
we did not detect mutations in whole genome sequencing data (Figure 3.8a, 3.8d). Thus, 
it is likely that reduction in Rftn1 expression is secondary to UCP1-knockout rather than 
the result of off-target mutagenesis. Taken together, these data suggest that BAd-
CRISPR knockout does not lead to substantial off-target mutations.  
 
DISCUSSION 
Although viral CRISPR/Cas9 delivery has proved a powerful tool for manipulating the 
somatic genome in liver, lung, heart, skeletal muscle, small intestine, thymus, and the 
central nervous system, it has not been reported in white or brown adipose tissues (17,19-
25). The adipose field is thus heavily reliant upon the use of transgenic mice which require 
significant time and investment. With nearly 40% of adults in the United States considered 
obese, more efficient strategies to study adipose tissues are required to improve our 
understanding of how these tissues contribute to obesity and to identify potential 
therapies (73). BAd-CRISPR inducible gene knockout distills the laborious process of 
generating a transgenic mouse into two basic steps: constructing an AAV8-sgRNA and 
administering it to the interscapular BAT of Cas9-expressing mice. Our method couples 
the novelty of CRISPR/Cas9 with the established Cre/LoxP system to enable highly 
efficient inducible gene knockout in BAT. While we implemented this model for BAT using 
BAd-CRISPR mice, it is easily amendable to any cell or tissue by crossing the Cre-
dependent Rosa26-LSL-Cas9 mice with a tissue specific promoter-driven Cre line (23). 
Using our cloning strategy, a sgRNA can be incorporated into the AAV expression vector, 
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validated in vitro, used to generate any AAV serotype, and delivered to a tissue of interest. 
Our work has thus shown for the first time that CRISPR/Cas9 can be harnessed to 
significantly improve our understanding of BAT. We anticipate that with further 
optimization it should be applicable to white and marrow adipose tissues too.  
We designed and validated highly efficient sgRNAs (53-88%) that caused 
frameshift mutations in cultured cells in >92% of the total sequences. In general, we 
prioritized sgRNAs that targeted early coding regions of the gene to introduce a frameshift 
mutation and disrupt translation of the mRNA. We also observed profound suppression 
of mRNA expression for each targeted allele, suggesting a mechanism for inhibiting gene 
transcription. Rational design and validation of sgRNAs in vitro allowed us to select highly 
efficient sgRNAs for gene knockout in vivo. We showed that a single administration of 
AAV8-sgRNA to the interscapular BAT resulted in near total knockout of Adipoq, Atgl, 
Fasn, Plin1, Scd1, and Ucp1 specifically in brown adipocytes. We also showed that 
multiple sgRNAs could be administered simultaneously using different AAV8 vectors. 
Morphologically, we observed striking differences between the BAT of mice administered 
AAV8-ATGL sgRNA, AAV8-PLIN1 sgRNA or a combination of the two. Ideally, future 
iterations of BAd-CRISPR will entail multiple sgRNAs cloned into a single AAV expression 
vector. In our model, we were limited by packaging restrictions from the mCherry 
fluorescent marker, which we included to quantify transduction efficiency. However, 
based on our data, it is apparent local AAV8 administration to the interscapular BAT leads 
to robust transduction and subsequent gene knockout. As such, the mCherry marker 
could be replaced with multiple U6 promoter-driven sgRNAs to different genomic targets. 
Packaging multiple sgRNAs into a single AAV is advantageous over multiple AAVs to 
deliver single sgRNAs as only one viral particle needs to transduce a brown adipocyte for 
gene knockout. Moreover, packaging the sgRNA along with Cas9 into one AAV could 
provide an all-in-one system for inducible gene knockout. Novel Cas9 orthologs smaller 
than S. pyogenes Cas9 (~1300 amino acids [aa]) such as N. meningitidis Cas9 (1082 
aa), S. aureus Cas9 (1053 aa), C. jejuni Cas9 (984 aa), and G. stearothermophilus Cas9 
(1089 aa) have all been identified for potential use to permanently modify the genome 
(74). Thus, future iterations may include more compact, highly efficient Cas9 orthologs, 
for an all-in-one AAV system. 
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BAd-CRISPR enabled us to generate the first inducible UCP1 knockout mouse 
model and determine that adult mice can defend core body temperature when cold 
stressed at 5ºC. We observed elevation of FGF21, which is known be upregulated in 
response to cold stress for adaptive thermogenesis (32,60,61). RNAseq identified 
dramatic changes to the transcriptome of BAT in BAd-CRISPR Ucp1 knockout mice. We 
observed an increase in peroxisomal β-oxidation and lipid metabolism genes along with 
a decrease in mitochondrial electron transport chain genes suggesting alternative 
adaptive thermogenesis mechanisms are activated in response to inducible UCP1 loss in 
adult mice. Gene profiling also suggests that thermogenesis in the absence of UCP1 may 
be accomplished by a futile cycle of increased protein synthesis and turnover. It is 
important to note that UCP1 loss was exclusive to the interscapular BAT, which in rodents 
is the largest BAT depot. However, mice also have smaller BAT depots located in the 
periaortic, perirenal, and intercostal depots which also express UCP1 (75,76). Therefore, 
it is likely classical UCP1-mediated adaptive thermogenesis also plays an ancillary role 
to help maintain body temperature in BAd-CRISPR Ucp1 knockout mice.  
Importantly, we did not detect evidence of substantial off-target mutations in vivo 
using unbiased whole genome sequencing and RNAseq. It is known that the total number 
of mismatched base pairs is a determinant for S. pyogenes Cas9 efficiency, and that 
PAM-proximal mismatches are less tolerated than more distal mismatches (70). Hsu et 
al. reported that 3 or more mismatches eliminated Cas9 cleavage activity at most genomic 
loci (70). In the example of Ucp1 sgRNA, we did not observe significant mutations at 7 
off-target loci. Each of these loci contained 3-4 base mismatches. Although 
CRISPResso2 detected mutations in 1.8% of the reads at the intergenic off-target site in 
chromosome 18, we did not detect any obvious signs of mutations at this locus using a 
genomic cleavage assay. While we cannot for certain rule out off-target mutations at this 
site, the data suggests off-target mutations are quite rare and thus non-substantial.  
While we have shown BAd-CRISPR is an efficient and versatile tool for generating 
inducible gene knockout in BAT, it is not without its limitations. For instance, BAd-CRISPR 
permanently alters the genome of brown adipocytes only, and thus gene expression is 
not altered in stromal vascular cells even if infected with AAV8-sgRNA. Moreover, 
precursor cells that subsequently differentiate into brown adipocytes are also not mutated, 
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and although adipocyte turnover in humans is estimated to be ~10% per year, long-term 
studies may necessitate additional injections for sustained knockout (77,78). For broader 
application of BAd-CRISPR to brown adipocytes, stromal vascular cells, and precursor 
cells, the Rosa26-Cas9 knockin mouse can be used. In this model, all cells express Cas9-
GFP, therefore, gene knockout is enabled in all cell types within a tissue. Indeed, we have 
shown that local injection of AAV8 to the interscapular BAT also leads to detectable 
transduction in liver, where expression of sgRNAs would be expected to cause mutations 
in Rosa26-Cas9 knockin mice. However, incorporating microRNAs into the AAV vector 
can limit transgene expression in off-target tissues. For example, Jimenez et al. added 
liver and heart specific microRNAs to AAV8 which significantly reduced transgene 
expression in each tissue, respectively (39). Thus, several strategies can be employed to 
modify BAd-CRISPR for targeted gene knockout in whole tissues. 
We have thus shown for the first time that CRISPR/Cas9 can be used for inducible 
gene knockout in BAT in vivo. Further optimization of AAV design and Cas9 technologies 
can improve BAd-CRISPR to target white or marrow adipose tissues for gene knockout, 
inactivation, or overexpression. Importantly, we have shown that BAd-CRISPR enables 
generation of transgenic animals with relative ease, less financial investment, and in 
significantly less time (1-2 months) compared to traditional approaches. We note, 
however, that our main objective was to provide ample evidence through multiple 
knockout models to show the efficiency of BAd-CRISPR. Thus, future work sufficiently 
characterizing the biological consequences of each inducible knockout in BAT of adult 
mice will be required. Therefore, we hope that BAd-CRISPR will prove useful to the field 
of adipose tissue and beyond for CRISPR/Cas9 inducible knockout in somatic tissues. 
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MATERIALS AND METHODS 
sgRNA Design and Cloning 
sgRNAs were designed using CRISPOR or the Synthego CRISPR Design tool (34). We 
selected sgRNAs that targeted early coding regions, did not have 0 or 1-base mismatch 
off-target sites, and had cutting frequency determination (CFD) scores >0.2. The 20-base 
sgRNA sequence was then used to synthesize a gBlocks Gene fragment that contained 
a U6 promoter and the sgRNA scaffold as well as the restriction sites PmlI and KpnI 
(Supplement 1) (IDT, Coralville, IA, USA). The AAV expression vector plasmid was 
generously provided by the University of Michigan Vector Core. We inserted PmlI and 
KpnI restriction sites into the AAV expression vector plasmid to enable cloning the U6-
sgRNA gBlocks (NEB, Ipswich, MA, USA). Digested AAV expression vector plasmid and 
sgRNA gBlocks were separated using gel electrophoresis and purified using the Wizard 
SV Gel and PCR Clean-Up System (Promega Corporation, Madison, WI, USA). sgRNA 
gBlocks were ligated into the AAV expression vector using T4 DNA ligase according to 
the manufacturer’s protocol (NEB, Ipswich, MA, USA).  
 
AAV Production 
AAV-sgRNA expression plasmids were transformed into competent DH5α E. coli (Thermo 
Fisher Scientific, Waltham, MA, USA). Plasmids were then isolated using the Qiagen 
Plasmid Maxi Kit (Qiagen, Hilden, Germany). Plasmids were sequenced prior to being 
used to generate AAVs (Eurofins Genomics, Louisville, KY, USA). All AAV8-sgRNAs 
were prepared by the University of Michigan Vector Core. 
 
Cell Culture 
Primary adipocyte progenitor cells were isolated from the ears of Rosa26-Cas9 knockin 
mice (#024858, Jackson Lab, Ellsworth, ME, USA) as previously described and cultured 
at 5% CO2 (23,79). Sub-confluent cells were maintained in DMEM:F12 medium (Thermo 
Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Sigma-
Aldrich, St. Louis, MO, USA) and supplemented with 10 ng/mL recombinant basic 
fibroblast growth factor (PeproTech Inc., Rocky Hill, NJ, USA). AAV-sgRNA expression 
plasmids were transfected to Cas9 cells using Lipofectamine 3000 according to the 
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manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA, USA). Cells were 
collected 4 days after transfection and sorted using the Sony MA900 Cell Sorter operated 
by the University of Michigan Flow Cytometry Core. Cells were lysed and DNA isolated 
using the Genomic Cleavage Detection Kit (Thermo Fisher Scientific, Waltham, MA, 
USA). 
 
Assessment of Mutations 
Mutations were assessed using TIDE (https://tide.nki.nl/), the Synthego ICE Analysis tool 
(www.ice.synthego.com), and the Genomic Cleavage Detection Kit (Thermo Fisher 
Scientific, Waltham, MA, USA). For each of these assays, we designed primers that 
flanked the cut site and were >100 bp upstream and downstream from the sgRNA binding 
site. DNA was amplified using Platinum SuperFi II DNA Polymerase (Thermo Fisher 
Scientific, Waltham, MA, USA). For TIDE and the Synthego ICE Analysis, amplicons were 
sequenced (Eurofins Genomics, Louisville, KY, USA), and traces were uploaded to the 
servers for analysis. The Genomic Cleavage Detection Kit was used according to the 
manufacturer’s protocol. Sequencing primers are listed in Supplement Table 3.1.  
 
Animals 
All mouse strains for this study originated at Jackson Labs (Bar Harbor, ME, USA). Cre-
dependent Cas9-GFP mice (Rosa26-LSL-Cas9, #026175), were bred with Ucp1 
promoter-Cre recombinase (B6.FVB-Tg(Ucp1-cre)1Evdr/J, #024670) to generate BAd-
CRISPR mice. Rosa26-Cas9 knockin mice (#024858) were also used. UCP1-deficient 
mice (Ucp1-/-, #003124) were generously provided by Dr. Liangyou Rui at the University 
of Michigan. Mice were housed in 12-hour light/12-hour dark cycles with free access to 
food and water. Temperature was set at 20-21ºC, and room humidity at 28-38%. For cold 
stress studies, mice were single housed without nesting materials in thermal chambers 
for 24 hours at 5ºC. Telemeters were implanted into the abdominal cavity to measure core 
body temperature and surgeries were performed by the Michigan Mouse Phenotyping 
Center. All animal studies were approved by and conducted in compliance with the 
policies of the University of Michigan Institutional Animal Care and Usage Committee. 
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Daily care of mice was overseen by the Unit for Laboratory Animal Medicine at the 
University of Michigan. Genotyping Primers are listed in Supplement Table 3.1.  
 
AAV8 Injection 
AAV8 injections were performed as previously described (26,45). In brief, female or male 
8-10-week-old BAd-CRISPR, Rosa26-LSL-Cas9, or Rosa26-Cas9 knockin mice were 
singled-housed 24-hours prior to injection. Mice were anesthetized with 2-4% inhaled 
isoflurane in O2 and a small area in the interscapular region was shaved to access BAT. 
A 1-2 cm incision was made, and the skin was peeled back to visualize the interscapular 
BAT. AAV8-sgRNAs were diluted in PBS (1012 vg/mL or 1010 vg/mL as indicated) to a 
final volume of 100 μL and injected into the interscapular BAT by carefully inserting the 
needle into each lobe at 2-3 distinct spots and dispensing the virus (~50 μL per BAT lobe). 
Body weight and food intake were monitored daily to ensure mice were healthy. 
 
Quantitative PCR 
Total RNA was purified from frozen tissue using RNA STAT-60 (Tel Test, Alvin, TX, USA) 
according to the manufacturer’s instructions. One μg of total RNA was reverse-
transcribed to cDNA using M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, CA, 
USA). qPCR was performed using a StepOnePlus System (Applied Biosystems, Beverly 
Hills, MI, USA). All qPCR primers were validated with a cDNA titration curve and product 
specificity was evaluated by melting curve analysis and gel electrophoresis of the qPCR 
products. Gene expression was calculated using a cDNA titration curve within each plate 
and then normalized to the expression of peptidylprolyl isomerase A (Ppia) mRNA. qPCR 
primers are listed in Supplement Table 3.2. 
 
RNAseq 
Total RNA was isolated as described using RNA STAT-60 (Tel Test, Alvin, TX, USA) and 
treated with DNAse. Samples were submitted to Beijing Genomics Institute (BGI, Beijing, 
China) for quality control, library preparation, and paired-end sequencing to generate 101 
base pair reads using DNB-SEQ-G400 platform. FASTQ files were downloaded for each 
sample. The quality of raw read data was checked using FastQC (version v0.11.9) to 
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identify features of the data that may indicate quality problems (low-quality scores, over-
represented sequences, inappropriate GC content) and filtered using fastp (version 
0.21.0). Reads were aligned to the GRCm39 reference genome (Ensembl version 104) 
and quantified using STAR (version 2.7.7a). Quality control was performed on the read 
tables to ensure adequate depth, knockout of Ucp1, and to identify outlier samples. 
Differential expression analysis was done using DESeq2 (version 1.30.1). Plots were 
generated using variations or alternative representations of native DESeq2 plotting 
functions, ggplot2, plotly, and other packages within the R environment (version 4.0.3). 
To compare BAd-CRISPR Ucp1 and Ucp1-/- mice, RPKM values were taken from GEO 
entry GSE127251. The expression levels of genes between BAd-CRISPR Ucp1 and 
UCP1-/- mice were compared using DESeq2. The resulting data was filtered for genes 
with significant differential expression (adjusted p-value < 0.05). FASTQ files, along with 
count tables and metadata, can be accessed at GSE176453. All analysis code can be 
found at github.com/alanrupp/romanelli-jbiolchem-2021.  
 
Immunoblot Analysis 
Frozen tissues were homogenized in 1% NP-40, 120 mM NaCl, 50 mM Tris-HCl; pH 7.4, 
50 mM NaF, 1x protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA) as 
previously described (80,81). Homogenate was centrifuged at 18,000 x g for 10 minutes 
at 4ºC. Protein concentration was determined using the BCA protein assay (Thermo 
Fisher Scientific, Waltham, MA, USA). Samples were diluted to equal protein 
concentrations in lysis buffer and SDS sample buffer (20 mM Tris; pH 6.8, 2% SDS, 
0.01% bromophenol blue, 10% glycerol, 5% 2-mercaptoethanol) and heated at 95ºC for 
5 minutes. Proteins were separated by SDS-PAGE on 4-12% gradient polyacrylamide 
gels (Invitrogen, Carlsbad, CA, USA) and transferred to Immobilon PVDF membranes 
(Millipore, Billerica, MA, USA). Membranes were blocked in 5% non-fat dried milk in Tris-
buffered saline (pH 7.4) containing 0.05% Tween-20 (TTBS) for 30 minutes at room 
temperature and then immunoblotted with the indicated primary antibodies (1:1000) in 
5% BSA in TTBS overnight at 4ºC. Blots were probed with horseradish peroxidase-
conjugated secondary antibodies (1:5000) diluted in 5% non-fat dried milk in TTBS for 2.5 
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hours at room temperature and visualized with Clarity Western ECL Substrate (Bio-Rad, 
Hercules, CA, USA). Antibodies are listed in Supplement Table 3.3.  
 
Histology 
Soft tissues were harvested and fixed in 10% neutral buffered formalin overnight at 4ºC. 
Tissues were then dehydrated in an ethanol gradient (30% for 30 minutes, 50% for 30 
minutes, 70% indefinitely) and prepared for paraffin embedding. Paraffin-embedded 
tissues were sectioned at 5 μm thickness and stained with hematoxylin and eosin (H&E) 
as previously described (82). Stained sections were imaged using a Zeiss inverted 
microscope at 100x or 200x magnification. 
 
ELISA 
Serum collected from mice was analyzed for circulating FGF21 using the Mouse/Rat 
FGF-21 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) by following the 
manufacturer’s protocol.  
 
Immunofluorescence Analysis 
Blocks of paraffin-embedded BAT from AAV8-sgRNA ATGL, AAV8-sgRNA PLIN1, and 
AAV8-Control sgRNA injected mice (n =3 mice) were sectioned at 5 µm and floated onto 
microscope slides in a 39˚C water bath. Paraffin was removed from sections by 3 
sequential 5 minute washes in 100% xylene. Sections were next rehydrated in a series 
of ethanol washes from 100%, 95%, 70%, and 50% with each concentration consisting 
of two 10 minute washes, followed by two 5 minute washes in deionized water. Antigen 
retrieval was achieved by a 20-minute incubation in sodium citrate buffer (10 mM sodium 
citrate, 0.05% Tween-20, pH 6.0) at 95˚C. Sections were cooled to room temperature, 
circled by a hydrophobic barrier, then washed twice in deionized water for 5 minutes. 
Sections were permeabilized with 0.2% Triton X-100, 1X PBS for 10 minutes and blocked 
in 10% normal donkey serum prepared in TNT buffer (0.1 M Tris-HCl pH 7.4, 0.15 M 
NaCl, 0.05% Tween 20) for 1 hour. Primary antibodies against ATGL (1:200), UCP-1 
(1:100), endomucin (1:250), and PLIN1 (1:100), were prepared in 2.5% normal donkey 
serum in TNT buffer then centrifuged at 15,000 x g for 10 minutes to remove aggregates. 
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Sections were incubated in primary antibody dilutions for 16 hours at 4˚C. Sections were 
washed three times in TNT buffer for 5, 10, then 15 minutes. Conjugated secondary 
antibodies against rabbit, goat, and rat were diluted 1:100 in TNT buffer then centrifuged 
at 15,000 x g for 10 minutes to remove aggregates. Sections were incubated in secondary 
antibody dilutions for 1.5 hours at room temperature then washed twice for 5 then 10 
minutes. Nuclei were stained with 14.3 µM DAPI in PBS for 5 minutes then washed twice 
in 1X PBS for 5 minutes. No. 1.5 coverslips were mounted to the slides with ProLong 
Gold mountant (Thermo Fisher Scientific, Waltham, MA, USA) and cured for 2 days at 
room temperature prior to imaging. Immunofluorescent microscopy was performed using 
a Nikon A1 laser scanning confocal with Plan Apo VC 60x oil DIC N2 objective. Antibodies 
are listed in Supplement Table 3.3.  
 
Whole Genome Sequencing 
Whole genome sequencing was performed by the University of Michigan Advanced 
Genomics Core using a NovaSeq 6000 system (Illumina, Inc., San Diego, CA, USA). 
Genomic DNA quality control and NGS library prep services were all performed by the 
University of Michigan Advanced Genomics Core. FASTQ files were aligned using the 
mouse genome (Ensembl GRCm38) with bowtie2 (version 2.3.5.1). Indels were identified 
with CRISPResso2 (version 2.0.45) and visual inspection within the Integrative Genomics 
Viewer (71).  
 
Statistics 
All data are presented as mean ± SD. When comparing two groups, significance was 
determined using Student’s two-tailed t-test. When comparing multiple experimental 
groups, an analysis of variance (ANOVA) was followed by post hoc analysis with 
Dunnett’s or Sidak’s test as appropriate. Differences were considered significant at p < 
























Supplement 3.1. sgRNA cloning sequences. (a) U6 promoter-driven sgRNA gBlocks 
template. The template contains the U6 promoter (green), a 20-bp sgRNA without the 
PAM (red), the sgRNA scaffold (blue), and a termination sequence (orange). The 
restriction sites for PmlI and KpnI flank the template and are bolded. The entire sequence 
(414-bp) is used to create a gBlocks Gene Fragment, digested using PmlI and KpnI, and 
ligated into the AAV expression vector. (b) sgRNA sequences, PAM sites, and CFD 







Figure 3.1. Transfection of adipocyte precursors with sgRNAs predominantly 
causes frameshift mutations in the target gene. (a) U6 promoter-driven sgRNAs were 
cloned into an AAV expression vector using PmlI and KpnI. The expression vector also 
contained CMV promoter-driven mCherry and 5’ and 3’ ITRs to facilitate packaging of the 
cassette into AAV8. (b-d) Sanger sequencing traces from Cas9-expressing adipocyte 
precursors transfected with AAV8-sgRNAs targeted to Adipoq, Atgl, and Plin1. For each 
target, primers (purple arrows) were designed upstream and downstream of the sgRNA 
cut site (yellow arrow). Chromatograms of the reverse strand are shown, and the cut site 
(black dotted line) and PAM (red underline) are displayed for each sgRNA. The highest 
frequency indels for each sgRNA and percent contribution as determined by TIDE and 
the Synthego ICE Analysis tool are shown. Frameshift mutations were calculated by 
dividing the number of frameshifts over the total number of mutations as estimated by the 






Supplement 3.2. BAd-CRISPR mice express Cas9 exclusively in BAT. (a) BAd-
CRISPR mice were generated by breeding Ucp1 promoter-Cre recombinase and Cre-
dependent Cas9-GFP mice (Rosa26-LSL-Cas9). (b) Immunoblot analyses showing 
Cas9, UCP1, ADIPOQ, and ERK2 expression with or without Ucp1-Cre. (c) Confocal 
microscopy of freshly dissected BAT, psWAT, pmWAT, and liver from Ucp1-Cre– or Ucp1-







Supplement 3.3. AAV8 direct injection robustly transduces interscapular BAT. (a) 
Confocal micrographs of freshly dissected tissue from Rosa26-Cas9 knockin mice 
administered 100 μL 1012 vg/mL AAV8-mCherry; 200x magnification; scale bar, 100 μm 
(n = 4). (b) mCherry mRNA expression; mRNA normalized to PPIA. Data shown are from 
female mice. Brown adipose tissue (BAT), posterior subcutaneous white adipose tissue 








Figure 3.2. BAd-CRISPR induces knockout of Adipoq, ATGL, FASN, PLIN1, and 
SCD1 in brown adipocytes of adult mice. (a-e) BAT mRNA and protein expression of 
BAd-CRISPR mice administered 100 μL 1012 vg/mL AAV8-sgRNA to Adipoq, Atgl, Fasn, 
Plin1, Scd1, or Control; mRNA expression was normalized to Ppia (n = 3-4). (f) 
Immunofluorescence analysis of paraffin-sectioned BAT from BAd-CRISPR Atgl mice 
stained for DAPI and immunolabeled against ATGL; 600x magnification, scale bar, 50 
μm. White arrows indicate brown adipocytes that were not mutated. Data shown are from 
male (Adipoq, Atgl, Fasn, Plin1, and Control) and female (Scd1 and Control) mice. Data 






Figure 3.3. BAd-CRISPR Atgl, BAd-CRISPR Plin1, and BAd-CRISPR Fasn inducible 
knockouts recapitulate previously described BAT phenotypes. (a) BAT weight (mg) 
of BAd-CRISPR mice administered 100 μL 1012 vg/mL AAV8-sgRNAs for Control, Atgl, 
Plin1, or Fasn (n = 3-4). (b) H&E staining of BAT; 200x magnification, scale bar, 50 μm. 
Data shown are from male mice and are presented as mean ± SD. * indicates significance 





Figure 3.4. BAd-CRISPR enables simultaneous knockout of ATGL and PLIN1 in 
brown adipocytes. (a) Freshly dissected BAT from Rosa26-LSL-Cas9 + AAV8-ATGL 
sgRNA and AAV8-PLIN1 sgRNA (BAd-CRISPR Control), BAd-CRISPR Atgl, BAd-
CRISPR Plin1, and BAd-CRISPR Atlg + Plin1 mice administered 100 μL 1010 vg/mL of 
the designated AAV8 (n = 2).  (b) BAT weight (mg) of Control, BAd-CRISPR Atgl, BAd-
CRISPR Plin1, and BAd-CRISPR Atgl + Plin1 mice. (c) H&E staining of BAT; 200x 
magnification, scale bar, 50 μm. Data shown are from male mice. Data are presented as 






Figure 3.5. BAd-CRISPR ablates UCP1 expression in brown adipose tissue. (a) 
Confocal micrographs of freshly dissected tissues from BAd-CRISPR Ucp1 mice 14 days 
after 100 μL 1012 vg/mL AAV8-UCP1 sgRNA injection; 200x magnification; scale bar, 50 
μm (n = 3). (b) mCherry mRNA expression at each timepoint, RNA expression normalized 
to Ppia (n = 3 mice per timepoint). (c) Genomic Cleavage assay of cDNA isolated from 
BAT. Red arrows indicate aberrant mutant PCR products. WT band = 320 bp. + or – 
indicates addition of the T7 endonuclease. (d) Sanger sequencing traces of cDNA from 
0 or 14 days post injection. The expected cut site is indicated with a dashed line and the 
PAM is underlined in red. Below, the sgRNA sequence is shown and the PAM is 
underlined and bolded. The purple arrow indicates the forward primer and sequencing 
direction. (e) mRNA expression of Ucp1 at each time point, RNA expression normalized 
to Ppia (n = 3 mice per timepoint). (f) UCP1 and adiponectin protein expression at 0, 2, 
7, or 14 days post AAV8-UCP1 sgRNA injection. Data shown are from female mice and 






Supplement 3.4. BAd-CRISPR Ucp1 ablates Ucp1 expression in adult mice. (a) H&E 
staining of BAT from 0, 2, 7, and 14-days post injection with AAV8-UCP1 sgRNA injection 
(100 μL 1012 vg/mL); 200x magnification; scale bar 50 μm (n = 3 mice per timepoint). (b-
c) UCP1 expression in Rosa26-LSL-Cas9 or BAd-CRISPR Ucp1 mice administered 
AAV8-UCP1 sgRNA. (d-e) UCP1 expression in BAd-CRISPR Control or BAd-CRISPR 
Ucp1 mice, mRNA normalized to PPIA. (f) Immunofluorescence of BAT from BAd-
CRISPR Control or BAd-CRISPR Ucp1 mice immunolabeled against UCP1 and 
endomucin, nuclei stained with DAPI; 600x magnification, scale bar 100 μm. White arrows 
indicate brown adipocytes that were not mutated. Data shown are from female mice. Data 






Figure 3.6. BAd-CRISPR Ucp1 inducible knockout mice defend core body 
temperature and have elevated FGF21. (a) 8-10 week old Rosa26-Cas9 knockin mice 
were implanted with a telemeter 7-days before injection with 100 μL 1012 vg/mL AAV8-
Control sgRNA or AAV8-UCP1 sgRNA and single housed at 20-21ºC with no enrichment 
for 14 days after injection. Mice were cold stressed at 5ºC for 24 hours and then sacrificed. 
(b) Ucp1 mRNA expression, mRNA normalized to Ppia (n = 4 or 5 mice). (c) Immunoblot 
showing UCP1 and Cas9 expression. (d-e) Body temperature at 20-21ºC and 5ºC. (f) 
Relative expression of thermogenic markers in BAT, mRNA normalized to Ppia. (g) 
Serum FGF21 concentrations in Rosa26-LSL-Cas9 (Control), Ucp1-/-, or BAd-CRISPR 
Ucp1 mice (n = 3, 4, or 5 mice). Data shown are from female mice. Data are presented 






Supplement 3.5. Body temperature, body weight, BAT weight, and food intake are 
not altered in BAd-CRISPR Ucp1 mice after 24 hour cold stress. (a) Body temperature 
after 24-hours at 5ºC. (b) Body weight (g) during 14 day recovery from AAV8 injection to 
the interscapular BAT. (c) Dissected BAT weight (mg). (d) Average daily food intake of 







Figure 3.7. Gene profiling of BAT from BAd-CRISPR Ucp1 mice suggests 
peroxisomal lipid oxidation and increased protein synthesis/turnover as a 
compensatory thermogenic process. (a) Violin plot of Ucp1 normalized transcript 
counts per million (CPM) (n = 4 or 5 mice). (b) Gene set enrichment analysis (GSEA) of 
the most up- and down-regulated pathways. (c) Heatmap showing the top coordinate 
regulated expression of genes whose proteins are associated with the peroxisome, lipid 
metabolism, mitochondrial metabolism, protein translation, and the proteasome. (d) Venn 
diagram depicting overlap of significant differential gene expression of Ucp1-/- and BAd-






Figure 3.8. CRISPR/Cas9 does not lead to observable off-target mutations in BAT 
of BAd-CRISPR Ucp1 mice. (a) Off-target sequence mismatches for UCP1 sgRNA 
predicted by CRISPOR and the Synthego sgRNA Design tool. The UCP1 sgRNA 
sequence is highlighted in yellow and base mismatches are colored red. Percent 
mutations were calculated using whole genome sequencing data visualized by the 
Integrative Genome Viewer (IGV) and CRISPResso2. (b) Indel characterization at the 
intergenic off-target determined by CRISPResso2. (c) Genomic cleavage assay at the 
intergenic off-target. WT band = 140 bp. (d) Heatmap of BAT gene expression for each 
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Discussion and Future Perspectives 
 
Viral and nonviral strategies to administer CRISPR/Cas9 for inducible gene knockout 
have proved revolutionary for modeling disease in a variety of tissues (1-10). While 
CRISPR/Cas9 has been applied to cultured preadipocytes and adipocytes, its use to 
inducibly knockout genes in adipose tissues of adult mice has not been reported (11-15). 
Indeed, targeting adipose tissues in vivo has remained elusive owing to their distribution 
across the body in unique depots and efforts to efficiently target adipocytes using AAVs 
or nonviral vectors have reported mixed results (16-18). Therefore, time consuming and 
resource costly transgenic mice are predominately used to model disease and study gene 
function in vivo. However, with the growing obesity epidemic, strategies to improve the 
way in which adipose tissues are studied are required. Thus, my doctoral work has 
developed the BAd-CRISPR method to enable rapid and efficient genome editing in BAT 
of adult mice and show for the first time that CRISPR/Cas9 can be applied to adipose 
tissue in vivo.  
BAd-CRISPR resulted in knockout of Adipoq, Atgl, Fasn, Plin1, Scd1, and Ucp1 
and recapitulated known BAT phenotypes, thereby demonstrating its scalability and utility. 
Importantly, it distilled the process of generating a transgenic mouse from 6-12 months 
to ≤2 months. Inducible knockout of UCP1 revealed striking changes to the transcriptome 
and suggested a combination of peroxisomal β-oxidation and protein synthesis/turnover 
as a compensatory mechanism to maintain body temperature in response to cold stress. 
These data show that BAd-CRISPR can be applied to further our understanding of BAT. 




What is the mechanism by which BAd-CRISPR Ucp1 inducible knockout mice 
defend core body temperature? 
Interestingly, BAd-CRISPR Ucp1 inducible knockout mice maintain body temperature at 
both room temperature (20-21ºC) and during a cold stress (5ºC) via an upregulation of 
pathways involved in fatty acid metabolism, the peroxisome, and protein 
synthesis/turnover and a decrease in pathways related to the mitochondrial electron 
transport chain and heat production by uncoupling proteins. We observed a similar 
phenomenon in RNAseq data from Ucp1-/- mice on a normal chow diet housed at 20ºC, 
which also had an upregulation of pathways involved in the peroxisome and lipid 
metabolism (19). These results suggest a reliance on peroxisomal β-oxidation of fatty 
acids to generate heat. β-oxidation of fatty acids occurs in both the mitochondria and 
peroxisomes of eukaryotic cells; however, oxidation of long chain fatty acids ≥26 carbon 
chain length occurs exclusively in peroxisomes (20,21). Both mitochondrial and 
peroxisomal β-oxidation follow the same enzymatic steps: removal of two hydrogens to 
produce a trans double bond between the α and β carbons, formation of 3-L-hydroxyacyl-
CoA, dehydrogenation of 3-L-hydroxyacyl-CoA to form 3-ketoacyl-CoA, and cleavage of 
the terminal acetyl CoA group to form a new acyl CoA molecule that is two carbons shorter 
(20). However, peroxisomal β-oxidation differs from mitochondrial β-oxidation in that 
peroxisomes lack a respiratory chain, and thus electrons from FADH2 are transferred to 
O2 to form H2O2 and energy is released as heat (20). These data thus provide evidence 
to support that peroxisomes may be involved in adaptive thermogenesis independently 
of UCP1 (20,22). 
Coupled with this, we also observed elevated expression of tRNA synthetase 
genes (Cars, Nars, Yars, Wars, Tars, Sars, Gars, Iars, and Eprs) in addition to genes 
coding for subunits of the proteasome. Collectively, this suggests a futile cycle in which 
de novo protein synthesis is required for adaptive thermogenesis and protection from 
cellular stress (23,24). Interestingly, we also see an upregulation of genes related to the 
proteasome in Ucp1-/- mice (19). Thus, dynamic changes to the transcriptome account 
for a compensatory thermogenic process in response to inducible loss of UCP1. However, 
the mechanism by which these contribute to the maintenance of body temperature 
remains to be elucidated.  
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Future work will thus seek to understand how peroxisomal β-oxidation and protein 
synthesis/turnover promote adaptive thermogenesis. Lipidomics analyses can identify 
how peroxisomal β-oxidation and/or α-oxidation contribute to heat production and further 
an understanding of how the peroxisome contributes to adaptive thermogenesis 
independently of UCP1. Additionally, proteomics analyses can shed insight into the 
nature of protein synthesis/turnover and help to identify how these counteractive 
processes defend body temperature. Comparing mitochondrial respiration of BAd-
CRISPR Ucp1, Ucp1-/-, and control mice can also indicate if metabolism is altered (25). 
Collectively, these experiments will further elucidate mechanisms by which inducible 
UCP1 knockout mice maintain adaptive thermogenesis. 
 
Can BAd-CRISPR be modified to target white and bone marrow adipose tissues?  
As we have demonstrated, BAd-CRISPR is an efficient method to inducibly knockout 
gene expression in BAT of adult mice. While we anticipate that BAd-CRISPR will 
positively impact the field of BAT research, we ultimately hope that this method will be 
broadly applied to the field of adipose tissue. To this point, significant progress must be 
made in transducing white and bone marrow adipose tissues. In preliminary studies, we 
were unable to demonstrate uniform transduction of psWAT following direct injection of 
AAV8 and AAV2. Additionally, our efforts to transduce bone marrow adipocytes via intra-
tibial injection of AAV8 have been unsuccessful. Thus, strategies to improve AAV 
transduction efficiency are required. Such strategies may involve capsid engineering to 
produce novel recombinant AAV serotypes that show affinity for white and bone marrow 
adipose tissues (17,18).  
The Bosch laboratory was the first group to comprehensively screen AAVs for 
adipocyte affinity by administering AAV1, AAV6, AAV7, AAV8, and AAV9 (26). Since this 
paper was first published in 2013, significant advances in AAV capsid engineering have 
been made to improve transduction efficiency (18,27-29). For example, directed evolution 
has generated libraries of capsid variants by random shuffling of capsid gene fragments, 
peptide display, or PCR-based mutagenesis (27,29,30). While these strategies have been 
used to tailor capsid variants for a wide array of cell types, few efforts have been made 
to engineer capsid variants for adipocytes (18). Of these, the hybrid serotype Rec2, which 
 110 
was generated by engineering capsid fragments from AAV8, cynomolgus macaque-
variant 5, rhesus macaque-variant 20, and rhesus macaque-variant 39, has been shown 
to effectively transduce adipose tissue (18,31). Using Rec2, the Cao laboratory has 
demonstrated robust transduction of BAT and WATs (32-35). Thus, future work should 
seek to package sgRNAs into Rec2 and assess transduction efficiency in WATs as well 
as in bone marrow adipose tissue. Considering the bone marrow adipose niche is much 
less understood, screening the known AAV serotypes (AAV1-AAV11) should be 
attempted as well. 
Beyond screening AAV serotypes and novel capsid variants, adjusting the viral 
dosage may improve transduction efficiency in WATs as well. To transduce adipose 
tissues, AAVs are generally dosed between 109 to 1012 vg/mL depending on the route of 
administration and depot (16-18). For BAd-CRISPR, 100 μL of 1012 vg/mL AAV8-mCherry 
was directly injected into the interscapular BAT (50 μL per BAT lobe). While this worked 
effectively for BAT, transducing WAT and bone marrow adipose tissues may require 
further dose optimization. Thus, performing a dose-response experiment in which AAV8-
mCherry is administered to white and bone marrow adipose depots at increasing dosages 
may help to optimize transduction on a depot-by-depot basis. Additionally, administering 
AAVs with nonionic surfactants such as Pluronic F88 has shown promise in transducing 
adipocytes as it has a low toxicity profile and can stabilize the cell membrane for improved 
uptake (36,37). Significant work is still required to apply BAd-CRISPR to additional 
adipose depots; however, through rational vector design and optimization of dosage, this 
method can significantly improve the field of adipose tissue research.   
 
What is the mechanism by which BAd-CRISPR suppresses gene expression? 
CRISPR/Cas systems can be broadly classified into two groups: Class I, in which multi-
subunit Cas proteins complex to facilitate cleavage, and Class II, in which a single Cas 
protein causes genomic cleavage (38-40). As such, the majority of studies employing 
CRISPR/Cas systems have utilized Class II, as it requires one Cas protein and can be 
packaged into viral vectors. BAd-CRISPR capitalizes on the Class II system and uses S. 
pyogenes Cas9 to generate frameshift mutations in genomic DNA and ablate gene 
expression. This process first occurs by the pairing of sgRNA to Cas9 to form a 
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ribonucleoprotein complex (41). The ribonucleoprotein complex then binds to the PAM 
sequence and unwinds the double-stranded genomic DNA, forming an RNA-DNA 
heteroduplex starting at the PAM-proximal region and extending distally down the sgRNA 
(42). Concomitantly, the non-target DNA strand forms a single-stranded DNA “R-loop” 
that causes Cas9 to undergo a conformational change and activates its two nuclease 
domains, HNH, and RuvC (43). HNH hydrolyzes the phosphodiester DNA backbone on 
the sgRNA-bound target DNA strand and RuvC hydrolyzes the PAM-containing non-
target DNA strand to cause a double-stranded break (44). The non-homologous end 
joining (NHEJ) repair pathway is then activated to fix the double-stranded break but is 
error prone and results in the formation of indels that cause frameshift mutations to disrupt 
gene expression (38).  
As we have shown, the BAd-CRISPR method resulted in complete knockout of 
Adipoq, Atgl, Fasn, Plin1, Scd1, and Ucp1. For each target, one sgRNA was used to 
target an early coding region of the gene. We demonstrated that sgRNAs primarily caused 
frameshift mutations in >90% of the mutated sequences and the majority of these were 
deletions of 1 base pair. Surprisingly, however, mRNA was virtually undetectable for each 
target gene knocked out using BAd-CRISPR. We performed quantitative PCR (qPCR) in 
exons upstream, downstream, or flanking the sgRNA cut site and consistently observed 
>80% reduction in mRNA expression regardless of the site amplified. These observations 
were perplexing, especially considering that whole genome sequencing of BAd-CRISPR 
Ucp1 mice revealed that only 36.1% of all genomic sequences had mutations at the 
sgRNA cut site. To explain this phenomenon, we postulate the following: i.) high incidence 
of nonsense mutations and rapid degradation of mRNA, ii.) large scale deletions of 
genomic DNA, or iii.) blocking of transcription. It is possible that one or a combination of 
these contribute to an inability to detect mRNA and thus warrant future study. 
Double-stranded breaks repaired by NHEJ result in indels of unpredictable length 
that can alter the coding frame and result in nonsense mutations which lead to truncated 
proteins (45,46). Typically, the cell employs nonsense-mediated decay to degrade mutant 
mRNA or nonsense-associated alternative splicing to remove the premature termination 
codon from the transcript (47,48). Given that all sgRNAs used in this study target the early 
coding region of each gene (exon 2 or exon 3) and given that frameshift mutations 
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predominated the observed mutation pool, it is therefore possible that BAd-CRISPR 
caused premature termination codons in the early coding region which led to nonsense-
mediated decay of mutant mRNA and thus prevented our ability to probe for gene 
expression using qPCR. It is also possible that a proportion of these frameshift mutations 
were repaired via nonsense-associated alternative splicing, as CRISPR/Cas9 genome 
editing has been shown to induce exon skipping (49). These mutations may also affect 
codon optimality, which has been shown to impact transcript stability (50,51). This might 
explain why we do not detect protein expression for each target gene, as unstable mRNA 
transcripts are rapidly degraded before being translated. Thus, nonsense mutations and 
rapid mRNA degradation may partially account for our inability to detect mRNA.  
A second explanation could be large scale deletions in genomic DNA. Several 
studies have reported on the rare incidence of indels spanning several hundred base 
pairs following CRISPR/Cas9 mutagenesis (52,53). Others have reported on the 
generation of inversions, endogenous and exogenous DNA insertions, and large 
deletions (54-56). Recently, Kosicki et al. showed that DNA breaks introduced by a 
sgRNA frequently resulted in deletions spanning many kilobases and argued that most 
studies miss these large scale deletions because they fail to amplify regions > 1 kilobase 
pairs around the target site (57). In another study, Cullot and colleagues demonstrated 
the rare incidence of megabase-scale chromosomal translocations from one double-
strand break (58). Indeed, we did not directly assess for the presence of large-scale 
deletions as sequencing amplicons were typically <500 base pairs in length. Although we 
performed whole genome sequencing on BAd-CRISPR Ucp1 mice, detection of large 
indels is challenging because of the short read lengths (~150 base pairs) generated by 
paired-end sequencing (59). Moreover, paired-end read mapping is insensitive to both 
small and large indel events because of the difficulty in separating small perturbations in 
read-pair distance from the normal background variability (59). Therefore, we cannot rule 
out the possibility of large-scale deletions in genomic DNA that arise from the BAd-
CRISPR method. Future work should employ single molecule, real-time sequencing to 
enable accurate long sequence reads.  
Lastly, a possible–albeit unlikely– explanation for an inability to detect mRNA is 
that the ribonucleoprotein complex binds to the genomic target, blocks the activity of RNA 
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polymerase II, and prevents transcription. Recently, Clarke et al. demonstrated that Cas9 
remains stably bound to DNA even after forming a double-stranded break and blocks 
access of NHEJ repair machinery, thereby reducing genome editing efficiency (60). Cas9 
can be dislodged by RNA polymerase II but only if it is annealed to the template DNA 
strand used by RNA polymerase II (60). Interestingly, the sgRNAs designed in this study 
bind to the non-template DNA strand. Thus, there is a possibility that Cas9 becomes 
bound and prevents the accumulation of indels, which may explain why we do not see 
more pronounced mutations in whole genome sequencing data of BAd-CRISPR Ucp1 
mice. While this phenomenon has not been reported in vivo and persistence of Cas9 
binding to template DNA in mammalian cells is debated, it is prudent to consider allele 
suppression as a potential mechanism by which BAd-CRISPR functions (61).  
 
Can BAd-CRISPR be used for more advanced CRISPR applications, such as base 
editing, CRISPRa, or CRISPRi? 
CRISPR affords the ability to do much more than cause indels and ablate gene 
expression. In fact, modifications to the CRISPR system have opened a wide array of 
tools for precision editing of the genome that can correct point mutations or 
overexpress/repress gene expression. It is our goal to implement these CRISPR systems 
to the BAd-CRISPR method to create a more robust technology with broad applications 
in adipose tissue research. 
To correct point mutations, programmable base editors have been developed 
using catalytically inactive Cas9 (dCas9) or Cas9 nickase fused to diverse functional 
domains (40). Unlike the traditional CRISPR/Cas9 system, base editors allow for site-
specific DNA base modification without generating double-strand breaks (62). Currently, 
there are two types of base editors: cytosine deaminase and adenine deaminase DNA 
base editors (63-66). As the name implies, cytosine deaminases catalyze the conversion 
of cytosine to thymine. First, dCas9 deaminates cytosine to uracil which results in a U-G 
mismatch that is then resolved by repair mechanisms to form a U-A base pair followed by 
a T-A base pair (62-64). This ultimately results in a C→T point mutation (62). By contrast, 
adenine deaminase base editors deaminate adenosine to yield inosine, which base pairs 
with cytosine and is corrected to guanine, to convert A→G or A-T into G-C (62,65,66). 
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Collectively, cytosine and adenine deaminase base editors enable C→T, T→C, A→G, 
and G→A transition mutations (67). Recently, prime-editing, a process by which reverse 
transcriptase is fused to Cas9 nickase, can generate any base transition (68). These 
technologies thus open the possibility of more precisely modeling disease in vivo. For 
example, several studies have applied AAVs to administer base editors to correct point 
mutations in Duchene muscular dystrophy and phenylketonuria and have also been 
optimized to achieve base editing in brain, liver, retina, heart, and skeletal muscles 
(67,69-71). Base editors are thus well suited for application in adipose tissue, as they can 
be packaged into AAVs and used to more closely model disease. Additionally, base 
editors have high efficiency and are better suited for adipocytes than homology directed 
repair (HDR), which is limited to the S/G2 phase of the cell cycle and therefore applicable 
to highly proliferating cell types only (40,72). Thus, mining genome-wide association 
studies from obese patients can identify single nucleotide polymorphisms which can then 
be modeled in mice by using base editors (73).  
Beyond permanently altering the genome through indels or base editing, CRISPR 
can also be used to manipulate gene expression without modifying the genetic code. In 
fact, dCas9 has been exploited to both overexpress or repress gene expression by fusing 
it to specific motifs (74). For overexpression, dCas9 has been fused to strong 
transcriptional activators such as VP64, VPR, SAM, or SunTag to induce gene 
expression, a process termed CRISPR activation (CRISPRa) (75-77). CRISPRa has 
recently been used to overexpress genes in preadipocytes and adipocytes in vitro (11,15). 
Lundh et al. stably expressed dCas9-VP64 in cultured preadipocytes and demonstrated 
significant upregulation of peroxisome proliferator-activated receptor-𝛾2 that promoted 
adipogenesis (11). Additionally, CRISPRa was used to upregulate Ucp1 expression in 
mature adipocytes in culture to mimic beiging. Wang et al. also applied CRISPRa to 
engineer human brown-like cells from white preadipocytes by upregulating Ucp1 
expression (15). Impressively, transplantation of CRISPRa-engineered human brown-like 
cells to obese mice improved glucose homeostasis and increased activation of 
endogenous BAT. While CRISPRa has nonetheless proved useful in cultured adipocytes, 
it has not been delivered to adipose tissues in vivo. Thus, future work incorporating 
CRISPRa to AAV8 can enable its use in a modified BAd-CRISPR method.  
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dCas9 can also be used to repress gene expression by binding to the DNA target 
sequence and preventing the activity of RNA polymerase II (74). To enhance repression, 
dCas9 has been fused to the Krüppel-associated Box protein and is referred to as 
CRISPR interference (CRISPRi) (78). Currently, CRISPRi gene repression in adipose 
tissue has only been reported by one study (79). Chung et al. utilized an oligopeptide 
complex to administer CRISPRi to repress Fabp4 expression and ameliorate obesity in 
mice. Surprisingly, knockdown of Fabp4 in the eWAT led to a 20% decrease in body 
weight, reduction in inflammation, reversal of hepatic steatosis, and improved insulin 
sensitivity in obese mice. As highlighted in Chapter I, these data should be interpreted 
with caution, as the authors fail to adequately explain the mechanism by which the 
oligopeptide complex is taken up by adipocytes and how suppression of Fabp4 in one 
adipose tissue contributes to such a marked change in whole body metabolism (17). 
 
Concluding remarks 
My doctoral work has demonstrated for the first time that the powerful gene editing tool 
CRISPR/Cas9 can be adapted to function in BAT of adult mice. The BAd-CRISPR method 
integrates well-established AAV gene transfer and Cre-Lox mouse models to facilitate 
targeted inducible gene knockout in BAT. Importantly, BAd-CRISPR is scalable, can be 
adapted to target virtually any gene, and does not lead to substantial off-target mutations. 
Indeed, continued research is still required to optimize delivery vectors and routes of 
administration for CRISPR/Cas9 inducible knockout in white or marrow adipose tissues 
and particular focus should be paid to how BAd-CRISPR suppresses mRNA expression. 
Ultimately, I hope this method advances the field of adipose tissue research and inspires 
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